

Consolidated Financial Statements and Supplementary Schedules

December 31, 2019 and 2018

(With Independent Auditors' Report Thereon)

Table of Contents

	Page(s)
Independent Auditors' Report	1–2
Consolidated Financial Statements:	
Consolidated Balance Sheets	3
Consolidated Statements of Operations	4
Consolidated Statements of Changes in Net Assets	5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7–40
Schedules	
Schedule 1 – Consolidating Schedule – Balance Sheet Information – December 31, 2019	41
Schedule 2 – Consolidating Schedule – Statement of Operations Information – Year ended December 31, 2019	42
Schedule 3 – Financial Responsibility Supplemental Schedule – Year ended December 31, 2019	43



KPMG LLP Suite 2000 303 Peachtree Street, N.E. Atlanta, GA 30308-3210

Independent Auditors' Report

To the Board of Directors
Grady Memorial Hospital Corporation:

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of Grady Memorial Hospital Corporation and affiliates (the System), which comprise the consolidated balance sheets as of December 31, 2019 and 2018, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Grady Memorial Hospital Corporation and affiliates as of December 31, 2019 and 2018, and the changes in their net assets and their cash flows for the years then ended, in accordance with U.S. generally accepted accounting principles.



Emphasis of Matter

As discussed in note 1(u) to the consolidated financial statements, in 2019 the System adopted new accounting guidance in connection with its implementation of Financial Accounting Standards Board Accounting Standards Update No. 2014-09, *Revenue from Contracts with Customers (Topic 606)*. Our opinion is not modified with respect to this matter.

Other Matter

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying 2019 consolidating supplementary information included in schedules 1 and 2 is presented for purposes of additional analysis, and is not a required part of the consolidated financial statements. The accompanying supplementary financial responsibility information in schedule 3 as of and for the year ended December 31, 2019 is presented for purposes of additional analysis, as required by the US Department of Education, and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audits of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated April 28, 2020, except as to note 22 and our report on the financial responsibility schedule, which are as of September 22, 2020, on our consideration of the System's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the System's internal control over financial reporting and compliance.



Atlanta, Georgia April 28, 2020, except as to note 22 and our report on the financial responsibility schedule, which are as of September 22, 2020.

Consolidated Balance Sheets

December 31, 2019 and 2018

(In thousands)

Assets	2019	2018
Current assets:		
Cash and cash equivalents \$	222,378	181,150
Patient accounts receivable, net	163,840	155,081
Grants receivable, net	15,133	18,983
Insurance proceeds receivable	10,021	_
Current portion of pledges receivable	16,493	19,239
Other current assets	79,818	59,725
Total current assets	507,683	434,178
Assets limited as to use	49,304	60,189
Property and equipment, net	419,124	413,900
Notes receivable, new market tax credit	37,024	37,024
Beneficial interest in net assets held by others	24,751	21,809
Pledges receivable, net, excluding current portion	10,399	12,537
Other assets	1,872	2,111
Total assets	1,050,157	981,748
Liabilities and Net Assets		
Current liabilities:		
Current portion of capital lease obligations \$	950	924
Accounts payable	45,602	41,335
Current portion of self-insurance reserves	12,462	13,008
Due to third-party payors, net	25,491	14,914
Due to Medical Schools	26,313	19,680
Other accrued expenses	92,719	82,356
Total current liabilities	203,537	172,217
Capital lease obligations, excluding current portion	32,484	33,434
Notes payable, net, new market tax credit	51,662	51,494
Self-insurance reserves, excluding current portion	39,897	41,219
Accrued postretirement benefit cost	1,358	2,203
Other long-term liabilities	7,336	7,243
Total liabilities	336,274	307,810
Net assets:		
Without donor restrictions	629,055	578,089
With donor restrictions	84,828	95,849
Total net assets	713,883	673,938
Commitments and contingencies		
Total liabilities and net assets	1,050,157	981,748

Consolidated Statements of Operations

Years ended December 31, 2019 and 2018

(In thousands)

		2019	2018
Revenue, gains, and other support:		_	
Net patient service revenue	\$	1,156,566	1,074,782
Contributions from Fulton and DeKalb Counties		55,435	55,435
Grant revenue		64,170	63,212
Other revenue	_	74,257	67,543
Total revenue, gains, and other support	_	1,350,428	1,260,972
Operating expenses:			
Salaries and benefits		583,724	543,464
Supplies and other expenses		679,202	631,899
Insurance proceeds from flood losses		(3,244)	_
Interest		4,130	4,076
Depreciation and amortization	_	61,496	56,954
Total operating expenses	_	1,325,308	1,236,393
Operating income	_	25,120	24,579
Nonoperating gains (losses), net:			
Investment income, net		3,873	2,795
Net periodic postretirement benefit credit		1,144	2,363
New market tax credit, net		(445)	(283)
Other	_	84	205
Total nonoperating gains, net	_	4,656	5,080
Revenue, gains, and other support in excess of			
expenses and losses		29,776	29,659
Accrued postretirement benefit cost adjustments Net assets released from restriction used for the purchase of		(535)	(1,414)
property and equipment		18,975	4,966
Contributions and other	_	2,750	6
Change in net assets without donor restrictions	\$	50,966	33,217

Consolidated Statements of Changes in Net Assets
Years ended December 31, 2019 and 2018
(In thousands)

Net assets, December 31, 2017 \$ 544,872 71,765 616,637 Revenue, gains, and other support in excess of expenses and losses 29,659 — 29,659 Accrued postretirement benefit cost adjustments (1,414) — (1,414) Net assets released from restriction used for purchase of property and equipment 4,966 (4,966) — Net assets released from restriction used for operations — (4,534) (4,534) Net change in beneficial interest in net assets held by others — 1,448 1,448 Contributions and other 6 32,136 32,142 Change in net assets 33,217 24,084 57,301 Net assets, December 31, 2018 578,089 95,849 673,938			Without Donor Restrictions	With Donor Restrictions	Total
of expenses and losses 29,659 — 29,659 Accrued postretirement benefit cost adjustments (1,414) — (1,414) Net assets released from restriction used for purchase of property and equipment 4,966 (4,966) — Net assets released from restriction used for operations — (4,534) (4,534) Net change in beneficial interest in net assets held by others — 1,448 1,448 Contributions and other 6 32,136 32,142 Change in net assets 33,217 24,084 57,301 Net assets, December 31, 2018 578,089 95,849 673,938	Net assets, December 31, 2017	\$	544,872	71,765	616,637
adjustments (1,414) — (1,414) Net assets released from restriction used for purchase of property and equipment 4,966 (4,966) — Net assets released from restriction used for operations — (4,534) (4,534) Net change in beneficial interest in net assets held by others — 1,448 1,448 Contributions and other 6 32,136 32,142 Change in net assets 33,217 24,084 57,301 Net assets, December 31, 2018 578,089 95,849 673,938	of expenses and losses		29,659	_	29,659
for purchase of property and equipment 4,966 (4,966) — Net assets released from restriction used for operations — (4,534) (4,534) Net change in beneficial interest in net assets held by others — 1,448 1,448 Contributions and other 6 32,136 32,142 Change in net assets 33,217 24,084 57,301 Net assets, December 31, 2018 578,089 95,849 673,938	adjustments		(1,414)	_	(1,414)
for operations — (4,534) (4,534) Net change in beneficial interest in net assets held by others — 1,448 1,448 Contributions and other 6 32,136 32,142 Change in net assets 33,217 24,084 57,301 Net assets, December 31, 2018 578,089 95,849 673,938	for purchase of property and equipment		4,966	(4,966)	_
assets held by others — 1,448 1,448 Contributions and other 6 32,136 32,142 Change in net assets 33,217 24,084 57,301 Net assets, December 31, 2018 578,089 95,849 673,938	for operations		_	(4,534)	(4,534)
Net assets, December 31, 2018 578,089 95,849 673,938	assets held by others		6_		•
	Change in net assets	,	33,217	24,084	57,301
	Net assets, December 31, 2018	,	578,089	95,849	673,938
Revenue, gains, and other support in excess of expenses and losses 29,776 Accrued postretirement benefit cost	·		29,776	_	29,776
adjustments (535) — (535)	adjustments		(535)	_	(535)
Net assets released from restriction used for purchase of property and equipment 18,975 (18,975) — Net assets released from restriction used	for purchase of property and equipment		18,975	(18,975)	_
for operations — (7,987) (7,987)	for operations		_	(7,987)	(7,987)
Net change in beneficial interest in net assets held by others — 2,942 2,942 Contributions and other 2,750 12,999 15,749	assets held by others		 2,750	•	•
Change in net assets 50,966 (11,021) 39,945	Change in net assets	•	50,966	(11,021)	
Net assets, December 31, 2019 \$ 629,055 84,828 713,883	•	\$			

Consolidated Statements of Cash Flows

Years ended December 31, 2019 and 2018

(In thousands)

		2019	2018
Cash flows from operating activities:			
Change in net assets	\$	39,945	57,301
Adjustments to reconcile change in net assets to net cash provided by operating activities:			
Depreciation and amortization		61,496	56,954
Gain on asset disposal		(83)	(81)
Amortization of debt issuance costs		168	168
Accrued postretirement benefit cost adjustments		535	1,414
Net change in beneficial interest in net assets held by others		(2,942)	(1,448)
Contributions used for the purchase of property and equipment		(4,192)	(25,261)
Changes in operating assets and liabilities:		(0.750)	(44 GEO)
Patient accounts receivable Grants and pledges receivable		(8,759) 8,734	(41,650) (19,668)
Insurance proceeds receivable		(10,021)	(19,000)
Other current assets		(20,093)	(4,497)
Other assets		232	(449)
Accounts payable, due to Medical Schools, and other accrued expenses and			,
liabilities		18,419	(10,455)
Due to third-party payors, net		10,577	816
Accrued postretirement benefit cost		(1,385)	(2,473)
Self-insurance reserves	_	(1,868)	7,192
Net cash provided by operating activities	_	90,763	17,863
Cash flows from investing activities:			
Purchase of property and equipment		(63,688)	(77,222)
Change in assets limited as to use	_	8,307	(7,961)
Net cash used in investing activities	_	(55,381)	(85,183)
Cash flows from financing activities:			
Principal repayments under capital lease obligations		(924)	(865)
Contributions used for the purchase of property and equipment	_	4,192	25,261
Net cash provided by financing activities	_	3,268	24,396
Net change in cash and cash equivalents		38,650	(42,924)
Cash and cash equivalents, beginning of year	_	194,385	237,309
Cash and cash equivalents, end of year	\$	233,035	194,385
Reconciliation of cash and cash equivalents:			
Cash and cash equivalents	\$	222,378	181,150
Cash funds in assets limited as to use		10,657	13,235
Total cash and cash equivalents	\$	233,035	194,385
Supplemental disclosure of cash flow information:			
Cash paid for interest	\$	4,344	4,287
Supplemental disclosures of noncash investing activities:			
Accrued expenses for additions to property and equipment	\$	11,647	8,705
		* =	-,

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(1) Organization, Business, and Summary of Significant Accounting Policies

Grady Memorial Hospital Corporation (the System) is a 501(c) (3) not-for-profit health system formed on March 17, 2008, which subsequently entered into a Lease and Transfer Agreement (the Agreement) effective June 1, 2008 with The Fulton-DeKalb Hospital Authority (the Authority). The System, located in Atlanta, Georgia, comprises Grady Memorial Hospital (the largest teaching hospital in the state), Hughes Spalding Children's Hospital (Hughes Spalding), five free-standing primary care clinics, and other significant healthcare facilities and services consistent with an integrated healthcare delivery and medical education system serving a major metropolitan area. The System has 953 licensed beds and is the principal safety-net healthcare provider for the Atlanta metropolitan area. In addition, the System maintains the primary Level I trauma center for the region.

The key terms and conditions associated with the Agreement are as follows:

- The System makes monthly lease payments to the Authority, totaling \$2.5 million in the initial year of the Agreement, and increasing each year by an amount generally measured by inflation in the published Consumer Price Index (CPI), not to exceed 3%, for an initial term of 40 years.
- The System assumed the liabilities of the Authority related to its previous operation of the former Grady Memorial Hospital and related facilities.
- In exchange for the lease payments and assumption of liabilities, the Authority transferred to the System all of the Authority's right, title, and interest in the operating assets of Grady Memorial Hospital and provided to the System the right to use its related facilities.
- The System is the agent for the Authority with respect to pre-existing Operating Agreements among the Authority, Fulton County, and DeKalb County. The Operating Agreements define the obligations of the Authority with respect to (principally) the provision of indigent care to the citizens of Fulton and DeKalb Counties (the Counties), in exchange for related ongoing funding that the Counties provide. The Authority is obligated to remit directly to the System all such funds the Authority receives from the Counties.

Certain assets and obligations of the Authority were excluded from the Agreement. In particular, the Authority retained certain assets and obligations related to (a) its sponsorship of The Fulton-DeKalb Hospital Authority Employee Pension Plan (the Plan – a frozen plan effective May 19, 2008) and (b) pre-existing Authority hospital revenue bond issues.

The Authority has defined obligations within the Agreement related to how it will apply the lease payments to its own obligations. A portion of the lease payments is to be applied to the Authority's ongoing funding of the Plan, and the Agreement requires that the System fund any shortfall between required Plan funding and available funds from the lease payments. Should there be an excess of lease payments over the Authority's bona fide operating costs and pension obligations, such excess must be returned to the System. The Authority may not carry over excess funds from year to year. No such funds were received by the System for the years ended December 31, 2019 and 2018.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

The System's acquisition of assets and assumption of liabilities under the Agreement was accounted for as a purchase. The System has recognized a capital lease obligation for the lease payments (excluding any future CPI adjustments), which were discounted at 7.24%, representing management's best estimate of a fair value rate that might be available to the System on an unenhanced credit basis. Other acquired assets and assumed liabilities were recognized at their respective estimated fair values.

Because any future funding obligations of the System for the Plan are currently indeterminable, those payments (if any) are accounted for on a "pay-as-you-go" basis and recognized currently in expense as invoiced from the Authority. During each of the years ended December 31, 2019 and 2018, the System recognized approximately \$3.8 million in expense associated with its pension-funding obligation as described herein. At December 31, 2019 and 2018, all such pension-funding amounts were fully settled.

The Agreement subjects the System to a number of commercially typical covenants, principally related to continuance of its mission as a safety-net hospital system, maintenance of facilities, and financial and other reporting, including the System's obligation to deliver audited financial statements within 120 days of year-end.

The significant accounting policies used by the System in preparing and presenting its consolidated financial statements are as follows:

(a) Principles of Consolidation

The accompanying consolidated financial statements of the System include the accounts of Grady Memorial Hospital, Hughes Spalding, the Henry W. Grady Memorial Foundation, Inc. (the Foundation), Grady Health Resources, Inc. (GHRI), Grady WIC, Inc. (GWIC), and Reliant Emergency Specialties, Inc. (Reliant). All significant intercompany accounts and transactions are eliminated in consolidation.

(b) Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Significant items subject to such estimates and assumptions include the determination of contractual allowances, explicit and implicit price concessions, allowances for uncollectible pledges, reserves for general and professional liability claims, third-party payor settlements, and the actuarially determined benefit liability related to the System's postretirement benefit plan.

In addition, laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates related to these programs will change by a material amount in the near term.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(c) Cash and Cash Equivalents

Cash and cash equivalents consist of cash on hand, deposits with banks, and investments in highly liquid debt instruments with original maturities of three months or less, excluding amounts limited as to use. The System maintains its cash and cash equivalents in domestic bank deposit accounts. The System invests its cash and cash equivalents with high-credit quality federally insured institutions. Cash and cash equivalent balances with any one institution may be in excess of federally insured limits. The System has not realized any losses in such accounts and believes it is not exposed to any significant credit risk.

(d) Assets Limited as to Use and Investment Income

Investments in equity securities with readily determinable fair values and all investments in debt securities are measured at fair value in the accompanying consolidated balance sheets. Investment income items (including interest and dividends) are included in revenue, gains, and other support in excess of expenses and losses unless the investment income has donor restrictions.

Assets limited as to use include assets internally designated for capital acquisition and other uses, assets held by trustee under escrow agreements, an insurance guaranty trust fund, and funds limited by donors for specific purposes.

(e) Inventories

Inventories, consisting principally of medical supplies and pharmaceuticals, are stated at the lower of cost (first-in, first-out method) or net realizable value.

(f) Property and Equipment, Net

Property and equipment transferred to the System under the terms of the Agreement are stated at fair value at the date of transfer. Property and equipment acquired subsequently are stated at cost, with the exception of donated items, which are stated at fair value at the date of donation. Equipment held under capital lease obligations is initially recorded at the lower of estimated fair value or the present value of minimum lease payments. Provisions for depreciation are computed using the straight-line method based on the estimated useful lives of the assets. Equipment held under capital lease obligations is amortized using the straight-line method over the shorter of the estimated useful life or the lease term, and such amortization is included in depreciation and amortization in the accompanying consolidated statements of operations.

A summary of asset classes and related ranges of estimated depreciable lives is as follows:

Land improvements 3–8 years
Buildings and improvements 5–40 years
Machinery, equipment, and vehicles 3–20 years
Computer hardware and software 3–10 years

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(g) Notes Receivable, New Market Tax Credit

Notes receivable, new market tax credit relates to two New Market Tax Credit (NMTC) Program financing arrangements established during 2015 and 2017 (as described in note 6) that exceed one year and bear interest at a market rate based on the borrowers' credit quality and are recorded at face value. Interest is recognized over the life of the notes. The System does not require collateral for the notes and does not intend to sell these receivables.

An allowance for credit losses is determined on an individual note basis if it is probable that the System will not collect all principal and interest contractually due. The System considers the borrowers' historical payment patterns, credit ratings as published by credit rating agencies, and general and industry-specific economic factors in determining probability of default. Impairment is measured based on the present value of expected future cash flows discounted at the notes' effective interest rates. The System does not accrue interest when a note is considered impaired. When ultimate collectability of the principal balance of an impaired note is in doubt, all related cash receipts are applied to reduce the principal amount of such notes until the principal has been recovered and are recognized as interest income thereafter. Impairment losses are charged against the allowance and increases in the allowance are charged to bad debt expense. Notes are written off against the allowance when all possible means of collection have been exhausted and the potential for recovery is considered remote. The System resumes accrual of interest when it is probable that the System will collect the remaining principal and interest of an impaired note. The notes receivable have no allowance for doubtful accounts as of December 31, 2019 and 2018, which is the System's best estimate of the amount of credit losses.

(h) Donor Restricted Net Assets

Donor restricted net assets are those whose use by the System is restricted by the donor to a specific time period or purpose. When a donor restriction expires, these net assets are reclassified to net assets without donor restrictions and are reported in the consolidated statement of operations as net assets released from restrictions. Donor restricted net assets can also be restricted by donors to be maintained in perpetuity. These net assets consist primarily of the System's beneficial interest in indigent care and nursing scholarship funds held by the Authority. All of the earnings of the trust are donor-restricted for the System's use in providing indigent and charity care.

(i) Patient Care Service Revenue

The System has adopted Accounting Standards Update 2014-09: *Revenue from Contracts with Customers* (Topic 606) (ASU 2014-09) which requires revenue to be recognized when promised goods and services are transferred to customers in amounts that reflect the consideration to which the System expects to be entitled in exchange for providing patient care. These amounts are reported at estimated net realizable value due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations.

(j) Charity Care

The System provides care to patients who meet certain criteria under its financial assistance policies at amounts less than its established rates. Because the System does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(k) Revenue, Gains, and Other Support in Excess of Expenses and Losses

The accompanying consolidated statements of operations include revenue, gains, and other support in excess of expenses and losses. Changes in net assets without donor restrictions, which are excluded from revenue, gains, and other support in excess of expenses and losses (to the extent applicable in any particular year), include certain postretirement benefit plan accounting adjustments, donor-restricted contributions, and net assets released from restrictions used for purchase of property and equipment.

For purposes of presentation, transactions deemed by management to be ongoing, significant, or central to the provision of healthcare services are reported as revenue and expenses. Peripheral or incidental transactions are reported as nonoperating gains and losses.

(I) Promises to Give and Donor Restricted Gifts

Unconditional promises to give cash and other assets to the System are reported at fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the underlying condition is satisfied by the System or the date the donor's intention to give becomes a promise to give. Gifts are reported as donor restricted support if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, these net assets are reclassified as net assets without donor restrictions and are reported in the consolidated statements of operations as net assets released from restrictions.

Gifts of long-lived assets such as property and equipment are excluded from revenue, gains, and other support in excess of expenses and losses and are reported without restriction unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as donor restricted support. Absent explicit donor stipulations about how long those long-lived assets must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service.

The System applies Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 958-205-45, *Reporting of Endowment Funds* (ASC 958-205-45). ASC 958-205-45 provides guidance on the net asset classification of donor-restricted endowment funds for a not-for-profit organization that is subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act of 2006, and serves to improve disclosures about an organization's endowment funds (both donor restricted and board designated).

The System has recorded a beneficial interest in donor-restricted endowment funds (note 16(b)) held by the Authority and does not maintain any board-designated or other endowments. Net changes in the estimated fair value of beneficial interest in net assets held by the Authority are reflected as increases or decreases to net assets with donor restrictions in the accompanying consolidated statements of changes in net assets. The System's Board has interpreted Georgia's State Prudent Management of Institutional Funds Act as requiring the preservation of the fair value of an original donor-restricted endowment gift as of the gift date, absent explicit donor stipulations to the contrary. To the extent that income from any donor-restricted endowment fund is itself restricted to specific donor-directed purposes, such income is accounted for within donor restricted net assets until expended in accordance with the donor's wishes. Should additional donor-restricted endowments be received, the System would oversee individual donor-restricted endowments to ensure that the fair value of the original gift is preserved.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(m) Asset Retirement Obligations

The System recognizes a liability for legal obligations associated with asset retirements in the period incurred, if a reasonable estimate of the fair value of the obligation can be made. When the liability is initially recorded, the System capitalizes the cost of the asset retirement obligation by increasing the carrying amount of the related long-lived asset. Over time, the liability (a component of long-term liabilities in the accompanying consolidated balance sheets) is accreted to its present value each period, and the capitalized cost associated with the retirement obligation is depreciated over the useful life of the related asset. Upon settlement of the obligation, any difference between the cost to settle the asset retirement obligation and the recorded liability is recognized as a gain or loss in the consolidated statements of operations.

(n) Long-lived Assets

Long-lived assets, such as property and equipment and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the System first compares undiscounted future cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. Assets to be disposed of are separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale are presented separately in the appropriate asset-and-liability sections of the consolidated balance sheet. In the period in which the disposal group is sold or classified as held-for-sale, the results of its operations are classified as discontinued operations in the consolidated statement of operations.

(o) Income Taxes

The System has been recognized by the Internal Revenue Service as exempt from federal income tax under Internal Revenue Code Section 501(a) as an organization described in Section 501(c) (3), and therefore, related income is generally not subject to federal or state income taxes. The Foundation has been similarly recognized. GHRI and GWIC are exempt from federal income tax under Internal Revenue Code Section 501(a) as organizations described in Section 501(c) (2). Reliant is a taxable for-profit entity and is subject to federal and state income taxes; however, the tax accounts for this entity are nominal in fiscal years 2019 and 2018.

The System applies FASB ASC 740, *Income Taxes* (ASC 740), which addresses the accounting for uncertain income tax positions. ASC 740 provides guidance on when tax positions are recognized in an entity's financial statements and how the values of these positions are determined. There is no impact on the System's consolidated financial statements as a result of applying ASC 740.

(p) Postretirement Benefit Plan

The System applies the recognition and disclosure provisions of FASB ASC Topic 715, Compensation – Retirement Benefits (ASC 715). ASC 715 requires that the System recognize the unfunded status of its postretirement benefit plan in its consolidated balance sheet. ASC 715 also requires measurement of plan assets and benefit obligations as of the System's fiscal year-end.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

The System records annual amounts relating to its postretirement benefit plan based on calculations that incorporate various actuarial and other assumptions, including discount rates, mortality, assumed rates of return, turnover rates, and healthcare cost trend rates. The System reviews its assumptions on an annual basis and makes modifications to the assumptions based on current rates and trends when it is appropriate to do so. The effect of modifications to those assumptions is recorded as a change in net assets without donor restrictions and are amortized to net periodic cost (credit) over future periods using the corridor method. The System believes that the assumptions utilized in recording its obligations under its postretirement benefit plan are reasonable based on its experience and market conditions.

Net periodic costs are recognized as employees render the services necessary to earn the postretirement benefits.

(q) Commitments and Contingencies

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

(r) Flood Event

On December 7, 2019, a twenty-four inch water pipe burst between Grady Memorial Hospital's sixth and seventh floors. The resulting water flow was contained without any harm to patients but not before substantial water and structural damage occurred. This flood event damaged six nursing units on three floors and affected many other floors below as well. Consequently, the Hospital lost the use of 220 patient beds and had to move patients to other facilities for their care. Since December 2019, many service area volumes at the Hospital are reduced and are expected to return in late 2020 when the damaged areas have been repaired and renovated.

As of December 31, 2019, the System has recorded incurred losses of \$3.2 million and a loss on impaired assets of \$9.3 million related to the flood event. The incurred losses are included in operating expenses in the accompanying 2019 consolidated statement of operations, and the loss on impaired assets is included in non-operating gains (losses) in the accompanying 2019 consolidated statement of operations. The System has concluded that insurance recoveries for the full amount of incurred losses and loss on impaired assets are probable and reasonably estimated. The System received \$2.5 million in proceeds from insurance recoveries in December 2019 and recorded a receivable for insurance recoveries totaling \$10.0 million as of December 31, 2019. Of the amounts received and receivable, \$3.2 million is presented as an offset to 2019 operating expenses and \$9.3 million is presented as an offset to the loss on impaired assets in other non-operating revenue gains (losses).

In addition to actual losses incurred, the amount of business interruption loss incurred for the year ended December 31, 2019 is estimated to be approximately \$17.5 million. Insurance recoveries related to business interruption loss will be recognized when all the contingencies related to this event have been resolved.

(s) Reclassifications

Certain reclassifications have been made to the 2018 consolidated financial statements to conform to the 2019 presentation. These reclassifications had no impact on the results of operations, changes in net assets, or cash flows in the accompanying consolidated financial statements.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(t) Subsequent Events

During the fourth quarter of 2019, a novel strain of coronavirus (COVID-19) surfaced. The spread of COVID-19 around the world and in the U.S. during the first quarter of 2020 has caused significant volatility in the global financial markets, including those in the U.S. There is continued uncertainty as to the breadth and duration of this pandemic and the resultant market disruption. The System is currently evaluating the impact on its operations and financial condition of potential adverse effects specific to the System, including reduced normal patient volumes, capacity constraint and resource inefficiencies due to potential surge of COVID-19 patients, unfavorable payor reimbursement patterns and payor mix, and market-driven downward valuation of equity securities, among others.

On March 27, 2020, H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act, "the CARES Act", was signed into legislation. Funding opportunities for healthcare providers under the CARES Act include the Public Health and Social Services Emergency Fund to be distributed to eligible healthcare providers, Centers for Medicare and Medicaid Services Medicare Accelerated/Advanced Payment funding to accelerate three to six months of Medicare payments to eligible healthcare providers, and the Commercial Insurance/FEMA Public Assistance Program: Emergency Protective Measures for reimbursement for eligible emergency costs incurred. In addition to these provisions, the CARES Act also includes various other cash flow enhancement measures such as payroll tax deferrals and employee retention credits, among others. The System has and will continue to consider the provisions of the CARES Act to utilize available governmental funds to offset the immediate effects of the COVID-19 healthcare crisis.

The System has evaluated subsequent events through April 28, 2020, the date the consolidated financial statements were available to be issued, and determined that there are no additional items to disclose.

(u) Recently Issued Accounting Standards

The FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers, in May 2014. ASU 2014-09 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity should also disclose sufficient quantitative and qualitative information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. As a result, amounts previously classified as the provision for doubtful accounts in the 2018 consolidated statement of operations are now reflected as implicit price concessions and therefore included as a reduction to net patient service revenue. For the years ended December 31, 2019 and 2018, the System recorded approximately \$679.4 million and \$367.7 million, respectively, of implicit price concessions as a direct reduction of patient care service revenue that would have been recorded as provision for doubtful accounts prior to the adoption of ASC 606. For the years ended December 31, 2019 and 2018, the System recorded approximately \$235.0 million and \$71.3 million, respectively, as a direct reduction of patient accounts receivable that would have been reflected as allowance for doubtful accounts prior to the adoption of ASC 606. ASC 606 also requires expanded disclosures regarding the System's revenue recognition policies and significant judgments employed in the determination of revenue. The System adopted ASC 606 with a retrospective approach in 2019. Other than these changes in presentation and disclosure, the adoption of ASC 606 did not have a material impact on the accompanying consolidated balance sheets or statements of operations and changes in net assets for the years ended December 31, 2019 and 2018.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

In January 2016, the FASB issued ASU No. 2016-01, *Recognition and Measurement of Financial Assets and Liabilities* (ASU 2016-01). ASU 2016-01 addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The ASU is effective for not-for-profit entities for fiscal years beginning after December 15, 2018, with early adoption restricted to certain provisions and within certain time periods. Under the ASU, not-for-profit and private entities are no longer required to disclose fair value information concerning financial instruments measured at amortized cost such as long-term debt. This provision of ASU 2016-01 may be early adopted for financial statements which have not yet been issued or made available for issuance. The System early adopted this provision of ASU 2016-01 as of December 31, 2015. The implementation of the other provisions of ASU 2016-01 during fiscal year 2019 had no impact to the consolidated financial statements and related notes.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (ASU 2016-02). The amendments in ASU 2016-02 create FASB ASC Topic 842, Leases, and supersede the requirements in ASC Topic 840, Leases. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under ASC Topic 840. Under the guidance of ASU 2016-02, a lessee should recognize in the balance sheet a liability to make lease payments (lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The accounting applied by a lessor under ASU 2016-02 is largely unchanged from that applied under ASC Topic 840. In July 2019, ASU 2016-02 was delayed by FASB and is now effective for all non-public business entities for fiscal years beginning after December 15, 2019. The System will implement the provisions of ASU 2016-02 during fiscal year 2020. The System has not yet determined the impact of the new standard on its current policies for lessee accounting. The System currently expects ASU 2016-02 to add a right-of-use asset and a related lease liability to the consolidated balance sheet beginning in fiscal year 2020 in line with the overall lease commitments disclosed in note 13 based on the System's evaluation of the standard to-date. Management continues to evaluate the effects the standard will have on the consolidated financial statements and management's current estimate could materially change at time of adoption.

In August 2016, the FASB issued ASU No. 2016-14, *Presentation of Financial Statements of Not-for-Profit Entities (ASU 2016-14)*. ASU 2016-14 (1) reduces the number of net asset classes presented from three to two; (2) requires the presentation of expenses by functional and natural classification in one location; and (3) requires quantitative and qualitative disclosures about liquidity and availability of financial assets. The ASU is effective for annual financial statements issued for fiscal years beginning after December 15, 2017. The System implemented the provisions of ASU 2016-14 during fiscal year 2018 on a retrospective basis.

In August 2016, the FASB issued No. ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments – a consensus of the FASB Emerging Issues Task Force (ASU 2016-15). ASU 2016-15 amends ASC 230, Statement of Cash Flows, to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows with the intent of reducing diversity in practice with respect to eight types of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted and entities must apply the guidance retrospectively to all periods presented. The System implemented ASU 2016-15 for its fiscal year beginning January 1, 2019. The System's adoption of ASU 2016-15 did not have a material effect on the consolidated financial statements.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

In November 2016, the FASB issued ASU No. 2016-18, *Statement of Cash Flows (Topic 230): Restricted Cash (ASU 2016-18)*, which requires companies to present amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents on the statement of cash flows. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included in cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the consolidated statement of cash flows. If cash and cash equivalents are presented in more than one line item on the consolidated balance sheet, the amounts and corresponding line items must be disclosed and reconciled to the total cash and cash equivalents shown in the consolidated statement of cash flows, either on the face of the consolidated statement of cash flows or in the notes to the consolidated financial statements. The System implemented ASU 2016-18 for its fiscal year beginning January 1, 2019 and applied retrospective application to fiscal year beginning January 1, 2018. The System's adoption of ASU 2016-18 did not have a material effect on the consolidated financial statements.

In March 2017, the FASB issued ASU No. 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost (ASU 2017-07)*, which requires entities to present the service cost component of net benefit cost in the income statement line items where they report compensation cost, and all other components of net benefit cost in the income statement separately from the service cost component and outside of operating income, if this subtotal is presented. Additionally, the service cost component will be the only component that can be capitalized. ASU 2017-07 is effective in annual periods in fiscal years beginning after December 15, 2018. The standard requires retrospective application for the amendments related to the presentation of the service cost component and other components of net benefit cost, and prospective application for the amendments related to the capitalization requirements for the service cost components of net benefit cost. The System implemented ASU 2017-07 for its fiscal year beginning January 1, 2019. The System's adoption of ASU 2017-07 did not have a material effect on the consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-08, *Not-for-Profit Entities (Topic 958-605) Clarifying the Accounting Guidance for Contributions Received and Contributions Made (ASU 2018-08)* to further improve the scope and the accounting guidance for revenue recognition, to assist entities distinguishing between contributions (non-reciprocal) and exchange transactions (reciprocal) and to determine whether a contribution is conditional. The System implemented ASU 2018-08 for its fiscal year beginning January 1, 2019. The System's adoption of ASU 2018-08 did not have a material effect on the consolidated financial statements.

In May 2019, the FASB issued ASU No. 2019-06, Intangibles – Goodwill and Other (Topic 350), Business Combinations (Topic 805), and Not-for-Profit Entities (Topic 958) Extending the Private Company Accounting Alternatives on Goodwill and Certain Identifiable Intangible Assets to Not-for-Profit Entities (ASU 2019-06), which provides not-for-profit entities an open-ended effective date and unconditional one-time election to adopt the private company alternatives from Topic 350 and Topic 805. Topic 350 provides that an entity should amortize goodwill on a straight-line basis over 10 years, or less, if applicable. Accounting policy election is required to test goodwill for impairment at the entity or reporting unit level and requires testing for impairment when a triggering event occurs. Topic 805 requires customer related intangible assets that are not capable of being sold or licensed independently from the other assets of a business and all noncompetition agreements be amortized consistent with the period of goodwill amortization. The ASU requires election of Topic 350 if Topic 805 is elected. Topic 350 may be adopted without adoption of Topic 805. The System has not elected to apply the provisions of the ASU at this time.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(2) Principal Safety Net Healthcare Provider - Implications for the System

The System's formation was driven by the strategic vision of local business and community leaders who recognized the overriding importance of Grady Memorial Hospital in providing appropriately accessible healthcare for the indigent and other potentially under-served populations in the region. In short, the vision is founded on a deep desire to ensure that the System can both survive and thrive in an increasingly competitive and challenging healthcare industry environment. The System's ability to continue its mission on a long-term sustainable basis is a critical benefit to the citizens of both metropolitan Atlanta and the state of Georgia.

As indicated in note 1, the System is the principal safety-net healthcare provider for the Atlanta metropolitan area. Additionally, because the System is the primary Level I trauma center for the region (and for other reasons unique to the System), it also has some patient volumes from outside of the metropolitan area. The System's payor mix is heavily influenced by care to the uninsured and underinsured. The financing of the System's care for this critical population is provided through two key sources:

- Funding from the Counties, as described in note 1, which totaled approximately \$55.4 million for both the 2019 and 2018 fiscal years, included in contributions from Fulton and DeKalb Counties in the accompanying consolidated statements of operations.
- Funding from the combined state/federal Medicaid disproportionate share program (referred to in Georgia as the Indigent Care Trust Fund, or ICTF), which totaled approximately \$83.8 million and \$83.7 million for the 2019 and 2018 fiscal years, respectively, included in net patient service revenue in the accompanying consolidated statements of operations.

The System is largely dependent on the two financing sources described above to provide net cash from operations at levels sufficient to fund the System's operating activities in a manner consistent with its mission. Any material reduction in funds from these two financing sources would have a materially adverse impact on the System's financial results. Management recognizes the risks inherent in the System's dependence on these financing sources.

As previously noted, the System is the legal agent for the Authority's obligations to the Counties regarding the provision of indigent care to the Counties' citizens, under the terms of continuing Operating Agreements that obligate the Counties to fund the cost of that care according to certain defined criteria. To further clarify Fulton County's obligations (which have historically represented the significant majority of related funding), the Authority and Fulton County entered into a Memorandum of Understanding (the MOU), which effectively further memorializes the financial obligation of Fulton County under the Operating Agreements. System management views the MOU as an important additional level of confirmation ensuring that funding it receives from the Counties will continue at levels reasonably consistent with the services the System provides to the Counties' citizens. Nevertheless, funding under the Operating Agreements (as supplemented by the MOU) is necessarily subject to political and related implications arising from the Counties' budgeting and related processes, and therefore, there are no guarantees regarding future funding amounts beyond the commitments evidenced in the Operating Agreements.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

Under the provisions of the ICTF program, the System contributes funds to be used by the state in the Medicaid program that are then supplemented by federal funds, the aggregate of which are often referred to as consolidation dollars. The consolidation dollars are returned to the System as additional Medicaid inpatient reimbursement. The state Medicaid program is funded on a state fiscal year basis (the state maintains a June 30 fiscal year-end). As of December 31, 2019, the System has been approved to participate in the state fiscal 2020 ICTF program. In February 2020, the state fiscal 2020 ICTF program plan terms were finalized. Nevertheless, there can be no assurance that the specific funding levels associated with the System's future participation in this program will be maintained at or near historical levels, or that the program will not ultimately be discontinued or materially modified. Distributions of the annual ICTF funding are generally disbursed in semiannual lump sums, the timing of which varies from year to year. Estimated amounts outstanding under the ICTF program totaled \$12.7 million and \$11.4 million at December 31, 2019 and 2018, respectively, and are included in other current assets in the accompanying consolidated balance sheets.

Significant operational improvements have been achieved since the formation of the System and management remains focused on continuing to improve operational efficiencies and growing revenue.

An important goal in the creation of the System was the solicitation of contributions from community donors who had previously not significantly supported Grady Memorial Hospital. To that end, the System has received multiple commitments since its 2008 formation through December 31, 2019 for contributions and conditional grants to support the System's significant need to improve its capital asset base. These funds have been, and will be, directed to a number of important capital asset needs, including major clinical equipment upgrades, new information technology systems, and a new Center for Ambulatory Surgery Services (CASS). These capital asset additions support the System's important strategic goals of improving clinical quality, attracting commercial and other insured patients, providing physicians and other clinicians clinical equipment that is consistent with current standards of care, and creating support systems that optimize effectiveness and efficiency in both clinical and nonclinical information reporting.

The System's ability to continue to pursue its safety net mission in a manner consistent with otherwise-comparable institutions serving major metropolitan areas is dependent on a number of factors, the most important of which have been described above. A reasonably assured funds flow from the Counties, continued participation in the ICTF program at legacy levels (assuming no Medicaid expansion), achievement of continued operational improvement strategies, and enhanced community fund-raising support are all vital to the System's mission. Management believes that the System is well-positioned against the critical dependencies previously described, but also notes that any material variance from the System's expectations in any of these areas would have an associated material adverse effect on its financial condition and its results of operations.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(3) Other Current Assets

The composition of other current assets is as follows:

	December 31		
		2019	2018
		(In thous	ands)
Prepaid expenses	\$	12,984	11,303
Inventories		20,009	16,478
Due from state reimbursement programs		23,686	23,390
Due from HSOC, Inc. (Note 18(a))		17,665	2,600
Other current assets		5,474	5,954
	\$	79,818	59,725

(4) Assets Limited as to Use and Investment Income

The composition of assets limited as to use is as follows:

	Fair value hierarchy		Decemi	her 31
	level (note 1	6)	2019	2018
			(In thous	sands)
Internally designated for capital acquisition and other uses:				
Mutual funds Held by trustee under escrow agreements:	Level 1	\$	5,234	4,203
Cash and cash equivalents Insurance guaranty trust fund:	Level 1		2,332	4,961
Cash and cash equivalents	Level 1		8,325	8,274
Limited by donors for specific purposes:				
Cash and cash equivalents	Level 1		30,359	39,772
High yield mutual funds	Level 1		1,302	1,227
Common collective trust funds	Level 1	_	1,752	1,752
		_	33,413	42,751
		\$_	49,304	60,189

Investment income, net (of investment fees) represents interest and dividends and totaled approximately \$3.9 million and \$2.8 million for the years ended December 31, 2019 and 2018, respectively.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(5) Property and Equipment, Net

A summary of property and equipment, net is as follows:

	December 31		
	 2019	2018	
	(In thous	sands)	
Land and land improvements	\$ 3,062	3,062	
Buildings and leasehold improvements	417,542	405,330	
Furniture, fixtures and equipment	321,180	293,527	
Computer hardware and software	 126,503	115,723	
	868,287	817,642	
Less accumulated depreciation and amortization	 (500,231)	(444,120)	
	368,056	373,522	
Construction in progress	 51,068	40,378	
	\$ 419,124	413,900	

Depreciation expense for the years ended December 31, 2019 and 2018 totaled approximately \$61.5 million and \$56.6 million, respectively. Construction in progress at December 31, 2019 and 2018 principally consists of expenditures related to new construction and renovation of existing facilities. Current projects in process at December 31, 2019 are planned for completion at various dates through fiscal year 2022 at an estimated total remaining cost to complete of approximately \$367.8 million.

Equipment under capital lease obligations at December 31, 2019 and 2018, exclusive of amounts held under the Agreement and gross of accumulated amortization, is approximately \$8.2 million at both December 31, 2019 and 2018. Related accumulated amortization at December 31, 2019 and 2018 is approximately \$5.7 million and \$5.1 million, respectively.

(6) New Market Tax Credit (NMTC) Program

The System entered into certain transactions (the Transactions) with a bank (the Investor Member) and certain lenders on August 16, 2017 and April 17, 2015 to obtain financing through the NMTC Program sponsored by the U.S. Department of Treasury. The NMTC Program permits certain corporate taxpayers to receive a credit against federal income taxes for making Qualified Equity Investments (QEIs) in Community Development Entities (CDEs). The credit provided to the investor totals 39% of the initial value of the QEI and is claimed over a seven-year credit allowance period. Through the Transactions, GWIC and GHRI, both wholly owned subsidiaries of the System, were formed for the purpose of effecting the System's participation in the NMTC Program. In addition, Grady Atlanta Investment Fund, LLC (the Investment Fund), a wholly owned subsidiary of the Investor Member, was formed as part of the 2015 Transaction for the purpose of investing in the related and subsequent CDEs.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

2017 NMTC Transaction

As part of the 2017 Transaction, the System contributed \$15.7 million as a loan to the Investment Fund, and the Investor Member contributed \$7.4 million as an equity interest in the Investment Fund. The Investment Fund then made QEIs totaling \$22.0 million in exchange for an equity interest in three supporting CDEs. These CDEs then loaned \$21.8 million, which represents the funding received by the CDEs less certain suballocation reporting fees and other transaction expenses, to GWIC as qualified low-income community investment loans (2017 QLICI Notes), which are included in notes payable, net, new market tax credit (note 9) in the accompanying consolidated balance sheets. The 2017 QLICI Notes do not require annual principal repayments, are secured by all of the assets of GWIC, and have a legal maturity date of August 16, 2047 and an anticipated repayment date of August 16, 2024 upon the exercise of the put option by the Investor Member. In connection with the 2017 Transaction, the System entered into a put/call agreement with the Investor Member. Under the terms of the put/call agreement, the System has the right to purchase the Investor Member's interest in the 2017 QLICI Notes at a nominal put price of \$1,000 on August 16, 2024. If the put option is not exercised by the Investor Member on August 16, 2024, the System may exercise its right under the call provision to purchase the Investor Member's interest in the 2017 QLICI Notes at a nominal price of \$1,000 during the earlier of six months following August 16, 2024 or six months following receipt of a Non-Put Election Notice (as defined) provided the System is compliant with certain other requirements stipulated in the put/call agreement.

The System has control over the operations of GWIC, and therefore, the accounts of this entity are included in the accompanying consolidated financial statements. The System provided funding to the Investment Fund and received and recorded a note receivable as part of the NMTC Program. A summary of note receivable, new market tax credit associated with the 2017 Transaction is as follows:

		December 31	
		2019	2018
	(In thousands)		
Note receivable with interest paid annually at a rate of 1.08%			
to be fully settled on August 16, 2024	\$	15,711	15,711

2015 NMTC Transaction

As part of the 2015 Transaction, the System contributed \$21.3 million as a loan to the Investment Fund, and the Investor Member contributed \$13.5 million as an equity interest in the Investment Fund. The Investment Fund then made QEIs totaling \$31.0 million in exchange for an equity interest in three supporting CDEs. These CDEs then loaned \$30.4 million, which represents the funding received by the CDEs less certain sub allocation reporting fees and other transaction expenses, to GHRI as qualified low-income community investment loans (2015 QLICI Notes), which are included in notes payable, net, new market tax credit (note 9) in the accompanying consolidated balance sheets. The 2015 QLICI Notes do not require annual principal repayments, are secured by all of the assets of GHRI, and have a legal maturity date of April 7, 2035 and an anticipated repayment date of April 6, 2022 upon the exercise of the put option by the Investor Member. In connection with the 2015 Transaction, the System entered into a put/call agreement with the Investor Member. Under the terms of the put/call agreement, the System has the right to purchase the Investor Member's interest in the 2015 QLICI Notes at a nominal put price of \$1,000 on April 6, 2022. If the put option is not exercised by the Investor Member on April 6, 2022, the System may exercise its right under the call provision to purchase the Investor Member's interest in the 2015 QLICI Notes at a nominal price of \$1,000 during the earlier of six months following April 6, 2022 or

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

six months following receipt of a Non-Put Election Notice (as defined) provided the System is compliant with certain other requirements stipulated in the put/call agreement.

The System has control over the operations of GHRI, and therefore, the accounts of this entity are included in the accompanying consolidated financial statements. The System provided funding to the Investment Fund and received and recorded a note receivable as part of the NMTC Program. A summary of note receivable, new market tax credit associated with the 2015 Transaction is as follows:

		December 31		
		2019	2018	
	(In thousands)			
Note receivable with interest paid annually at a rate of 1.0%				
to be fully settled on April 6, 2022	\$	21,313	21,313	

(7) Pledges Receivable, Net

A summary of pledges receivable, net is as follows:

	December 31		
	 2019	2018	
	 (In thous	ands)	
Less than one year	\$ 16,493	19,239	
One to five years	 11,572	14,029	
	28,065	33,268	
Less:			
Unamortized discounts using a discount rate of 3.3%			
at both December 31, 2019 and 2018	(737)	(1,178)	
Allowance for doubtful pledges	 (436)	(314)	
	\$ 26,892	31,776	

(8) Other Accrued Expenses

The composition of other accrued expenses is as follows:

	December 31		
	 2019	2018	
	 (In thous	ands)	
Accrued salaries and benefits	\$ 47,950	43,253	
Current portion of accrued postretirement benefit cost	961	965	
Other accrued expenses	 43,808	38,138	
	\$ 92,719	82,356	

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(9) Notes Payable

A summary of notes payable, net, new market tax credit is as follows:

	December 31	
	2019	2018
	 (In thous	ands)
Notes payable associated with the 2017 NMTC Transaction (note 6), interest paid annually at an interest rate of 1.0%, anticipated to be fully settled on August 16, 2024 Less:	\$ 21,840	21,840
Unamortized debt issuance costs	 (306)	(373)
	 21,534	21,467
Notes payable associated with the 2015 NMTC Transaction (note 6), interest paid annually at an interest rate of 0.7%, anticipated to be fully settled on April 6, 2022	30,355	30,355
Less: Unamortized debt issuance costs	 (227)	(328)
	 30,128	30,027
Notes payable, net, new market tax credit	\$ 51,662	51,494

(10) Insurance Programs

The System is self-insured for its general and professional liability insurance coverage. The System's self-insured retention is \$5 million per claim and \$25 million in the aggregate. Commercial insurance has been obtained through various carriers to provide for excess and umbrella coverage of \$95 million in excess of the System's self-insured retention limits on a claims-made basis.

The general and professional self-insurance reserves included in the accompanying consolidated balance sheets, totaling \$50.1 million and \$52.4 million at December 31, 2019 and 2018, respectively, include estimates of the ultimate costs for both reported claims and claims incurred but not reported. The System has retained independent actuaries to estimate the ultimate costs of the settlement of such claims. Accrued general and professional liability costs have been undiscounted at December 31, 2019 and 2018.

The System is self-insured for its workers' compensation liability exposures up to limits of \$350,000 per claim. Commercial insurance has been obtained to provide for excess workers' compensation liability coverage. The related amounts recorded by the System in the accompanying consolidated balance sheets totaled \$2.3 million and \$1.9 million at December 31, 2019 and 2018, respectively (undiscounted at December 31, 2019 and 2018).

The System sponsors a self-insured program for its employee health benefits up to limits of \$285,000 per claim for fiscal years 2019 and 2018. The System recognized related reserves of approximately \$3.6 million and \$3.3 million in accrued medical benefits (included in other accrued expenses in the accompanying consolidated balance sheets) at December 31, 2019 and 2018, respectively. The reserves include estimates of the ultimate cost for claims incurred but not reported.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

In the opinion of management, adequate provision has been made for losses that may occur from the asserted and unasserted claims for each of these self-insurance programs.

(11) Net Patient Service Revenue

Net patient service revenue is reported at the amount that reflects the consideration to which the System expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government payors), and others and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. The System bills the patients and third-party payors several days after the services are performed or the patient is discharged from the facility. Revenue is recognized as the performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the System. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The System believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients receiving inpatient acute care, long-term care services and patients receiving services in outpatient centers. The System measures the performance obligation from admission into the hospital/nursing facility, or the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or completion of the outpatient services. Revenue for performance obligations satisfied at a point in time is generally recognized when goods are provided to the patients and customers in a retail setting (for example, pharmaceuticals), and the System does not believe it is required to provide additional goods or services related to that sale.

The System's performance obligations relate to contracts with a duration of less than one year; therefore, the System has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The System is utilizing the portfolio approach practical expedient in ASC 606 for contracts related to net patient service revenue. The System accounts for the contracts within each portfolio as a collective group, rather than individual contracts, based on the payment pattern expected in each portfolio category and the similar nature and characteristics of the patients within each portfolio. The portfolios consist of major payor classes for inpatient revenue and outpatient revenue. Based on historical collection trends and other analyses, the System has concluded that revenue for a given portfolio would not be materially different than if accounting for revenue on a contract-by-contract basis.

The System determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third party payors, discounts provided to uninsured patients in accordance with the System's policy, or implicit price concessions provided to uninsured patients. The System determines its estimates of contractual adjustments and discounts based on contractual agreements, discount policies, and historical experience. The System determines its estimate of implicit price concessions based on historical collection experience with certain classes of patients.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

Consistent with the System's mission, care is provided to patients regardless of their ability to pay. Therefore, the System has determined it has provided implicit price concessions to uninsured patients and other uninsured balances (for example, copays and deductibles). The implicit price concessions included in estimating the transaction price represents the difference between amounts billed to patients and the amounts the System expects to collect based on its collection history with those patients.

Patients who meet the System's criteria for charity care, services are provided free or at a discounted amount. These patients are not billed for their healthcare services. These amounts are recorded as charity care services and are not reported as revenue.

Patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The System also provides services to uninsured patients and offers those uninsured patients a discount, either by policy or by law, from standard charges. The System estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions based on historical collection experience. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change.

The System has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the following factors:

- Payors (for example, Medicare, Medicaid, managed care or other insurance, patient) have different reimbursement and payment methodologies
- Length of the patient's service or episode of care
- Method of reimbursement (fee for service or agreed-upon rates with payors)
- The System's line of business that provided the service (for example, inpatient, outpatient, nursing home, etc.)

The System has agreements with governmental and other third-party payors that provide for reimbursement to the System at amounts different from its established rates. Contractual adjustments under third-party reimbursement programs represent the difference between billings at established rates for services and amounts reimbursed by third-party payors. A summary of payment arrangements with major third-party payors is as follows:

Medicare – Substantially all acute care services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to patient classification systems that are based on clinical, diagnostic, and other factors. Certain types of exempt services and other defined payments related to Medicare beneficiaries are paid based upon cost reimbursement or other retroactive-determination methodologies. Payments for cost reimbursable items are made at tentative rates, with final settlement determined after submission of annual cost reports by Grady Memorial Hospital and audits by the Medicare administrative contractors. Grady Memorial Hospital's cost reports have been audited and settled for all fiscal years through 2012. Revenue from the Medicare program accounted for approximately 35% and 34% of the System's net patient service revenue for the years ended December 31, 2019 and 2018, respectively.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

Medicaid – Inpatient services rendered to Medicaid program beneficiaries are generally paid based upon prospective reimbursement methodologies established by the state of Georgia. Certain types of exempt services and outpatient services related to Medicaid beneficiaries are paid based upon cost reimbursement or other retroactive-determination methodologies. Payments for cost reimbursable items are made at tentative rates, with final settlement determined after submission of annual cost reports by the System and audits by the Medicaid fiscal intermediary. Grady Memorial Hospital's cost reports have been audited and settled for all fiscal years through 2016. The System also contracts with certain managed care organizations to receive reimbursement for providing services to Medicaid beneficiaries. Payment arrangements with these managed care organizations consist primarily of prospectively determined rates per discharge, discounts from established charges, or prospectively determined per diem rates. Revenue from the Medicaid program (excluding ICTF revenue) accounted for approximately 28% and 31% of the System's net patient service revenue for the years ended December 31, 2019 and 2018, respectively.

The System has also entered into other reimbursement arrangements providing for payment methodologies, which include prospectively determined rates per discharge, prospectively determined per diem amounts, and discounts from established charges.

As described in note 2, the System participates in the state ICTF program and an ancillary program referred to as the Upper Payment Limit (UPL) program. Net amounts received from the ICTF and UPL programs are recognized as additional Medicaid inpatient reimbursement and, therefore, are reflected in net patient service revenue. The related net reimbursement benefit recognized by the System for the years ended December 31, 2019 and 2018 was approximately \$103.6 million and \$112.8 million, respectively. The fact that the System's fiscal year-end differs from the state fiscal year results in certain timing differences in terms of ICTF and UPL funds received and to be received. The System's ICTF and UPL revenue is subject to retrospective adjustment in future periods based upon audits as required by the Centers for Medicare & Medicaid Services (CMS). Estimated amounts outstanding under the ICTF and UPL programs for fiscal years 2019 and 2018 totaled \$23.7 million and \$23.4 million, respectively, and are included in other current assets in the accompanying consolidated balance sheets.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various healthcare organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the System's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the System. In addition, the contracts the System has with commercial payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive revenue adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the System's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations.

Net patient service revenue increased by approximately \$1.1 million and decreased by \$0.7 million in 2019 and 2018, respectively due to the adjustment of previously estimated third-party payor reserves that are no longer necessary as a result of final settlements, years that are no longer subject to audits, reviews, and investigations, and new reserves established in accordance with the System's policy.

The composition of net patient service revenue based on the System's major financial classes and lines of business for the years ended December 31, 2019 and 2018 are as follows:

	 2019	2018
	 (In thous	ands)
Medicare	\$ 475,588	437,929
Medicaid	296,636	293,517
Other third-party payors	342,940	318,722
Uninsured - Self Pay	 41,402	24,614
	\$ 1,156,566	1,074,782
	 2019	2018
	(In thous	ands)
Business lines:		
Grady Hospital - inpatient	\$ 714,066	669,869
Grady Hospital - outpatient	223,071	204,402
Hughes Spalding Children's Hospital - inpatient	4,806	6,244
Hughes Spalding Children's Hospital - outpatient	44,229	38,463
Grady EMS Services	55,260	48,133
Crestview Nursing Facility	15,912	14,858
Pharmacy Outpatient Sales - Point of Sale Services	 99,222	92,813
	\$ 1,156,566	1,074,782

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

For the years ended December 31, 2019 and 2018, the System recognized revenue of \$953.7 million and \$869.1 million respectively, from goods and services that transfer to the customer over time and \$99.2 million and \$92.8 million, respectively, from goods and services that transfer to the customer at a point in time. Also, for the years ended December 31, 2019 and 2018 approximately \$103.6 million and \$112.8 million respectively from the ICTF and UPL programs; these revenues are recognized as additional Medicaid reimbursement.

Contract Assets

Under the provisions of ASU 2014-09, amounts related to services provided to patients for which the System has not billed and that do not meet the conditions of unconditional right to payment at the end of the fiscal year are contract assets. The System's contract assets consist primarily of services that the System has provided to patients who are still receiving inpatient care in the System's facilities at the end of the fiscal year. Such contract assets are included in patient accounts receivable, net in the accompanying consolidated balance sheet at December 31, 2019. The opening and closing balance of contract assets was \$16.9 million and \$22.7 million at January 1, 2019 and December 31, 2019, respectively.

Uncompensated Care

As further described in both notes 1 and 2, the System is the principal safety net healthcare provider for the Atlanta metropolitan area. As a result, the System provides significant amounts of healthcare services to a large number of uninsured citizens in the region, the majority of whom do not have the means to pay for the cost of services provided. Consistent with the System's mission, all patients are served without regard to ability to pay. Charity care is offered to residents of Fulton and DeKalb Counties in accordance with the System's financial assistance policies. While a significant number of uninsured patients apply and qualify for financial assistance, a large population of uninsured patients that are served by the System (especially those provided emergency care) are not eligible for financial assistance, and therefore, the System also incurs significant amounts of implicit price concessions related to the charges for services provided.

The System recognizes patient service revenue associated with services provided to patients with third-party payor coverage on the basis of contractual rates for the services rendered. For uninsured patients who do not qualify for its Financial Assistance Program, the System recognizes revenue on the basis of its discounted rates for services provided. Based on historical experience, a significant portion of the System's uninsured patients are unable or unwilling to pay for the services provided.

The System provides services to patients who do not have the ability to pay and who qualify for charity care services pursuant to established policies of the System. Charity care services are defined as those for which patients have the obligation and willingness to pay but do not have the financial wherewithal to do so. The System does not include charity care in net patient service revenue. The cost of charity care provided totaled approximately \$212.9 million and \$245.3 million for the years ended December 31, 2019 and 2018, respectively. The cost of uncompensated care, which is defined by the System as services related to patients who do not have the ability to pay including charity care, uninsured discounts, and implicit price concessions totaled approximately \$370.4 million and \$337.9 million for the years ended December 31, 2019 and 2018, respectively. The System estimated these costs by applying a ratio of cost to gross charges to the related gross uncompensated charges.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(12) Employee Benefits Plans

(a) Postretirement Medical Plan

The System provides retiree medical benefits covering all employees of the System who previously retired at age 55 or older with at least 10 years of service. In fiscal year 2008, the System amended this plan to limit availability of retiree medical benefits to current employees aged 50 or older on September 4, 2008 and who retire at age 62 or older with at least 10 years of service. The cost of providing most of these benefits is shared with the retirees. The plan is unfunded, and therefore, the System's participation is on a "pay-as-you-go" basis.

The plan was amended effective May 1, 2013, the terms of which generally provide that Medicare-eligible employees are no longer eligible for retiree medical benefits under the postretirement benefit plan. Consequently, during 2014 the System began providing a retiree Health Reimbursement Account (HRA) for each Medicare-eligible individual in the plan. The plan discontinued its HRA contributions starting in 2015. The financial impact of the 2013 plan amendments on the System's consolidated financial statements has resulted in a \$1.1 million and a \$2.4 million increase in operating income for the years ended December 31, 2019 and 2018 respectively, through a reduction in net periodic benefit cost. A discount rate of 3.35% was used to remeasure obligations at the amendment date.

The changes in the accumulated postretirement benefit obligation (APBO) during the years ended December 31, 2019 and 2018 are as follows:

	 December 31	
	2019	2018
	(In thousa	ands)
APBO, beginning of year:	\$ 3,168	4,227
Service cost	32	56
Interest cost	85	90
Plan participant contributions	32	45
Benefits paid	(236)	(19)
Actuarial gain	 (762)	(1,231)
APBO, end of year	\$ 2,319	3,168

The APBO amounts recognized in the accompanying consolidated balance sheets are as follows:

	_	December 31	
	_	2019	2018
		(In thous	sands)
Current liabilities	\$	961	965
Long-term liabilities	_	1,358	2,203
Amount recognized	\$_	2,319	3,168

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

The amounts accumulated in net assets without donor restrictions are as follows:

	December 31	
	2019	2018
	(In thousands)	
Net gain	\$ 1,926	2,425
	\$ 1,926	2,425

The total amount of actuarial net loss expected to be amortized into net periodic postretirement benefit cost in 2019 is a net debit of \$0.9 million.

Weighted average assumptions used to determine benefit obligations in the accompanying consolidated balance sheets are as follows:

	December	December 31		
	2019	2018		
Discount rate	2.03 %	3.37 %		
Rate of compensation increases	N/A	N/A		

The components of net periodic postretirement benefit cost (credit) are as follows:

	December 31		
		2019	2018
		(In thous	sands)
Service cost	\$	32	56
Interest cost		85	90
Amortization of prior service credit		_	(1,746)
Amortization of net gain		(1,261)	(763)
Net periodic postretirement benefit credit	\$	(1,144)	(2,363)

Weighted average assumptions used to determine net periodic postretirement benefit credit are as follows:

	December 31		
	2019	2018	
Discount rate	3.37 %	2.49 %	
Expected long-term rate of return on plan assets	N/A	N/A	
Rate of compensation increases	N/A	N/A	

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

Assumed healthcare cost trend rates of employer claim payments, which are based on a national 2019 survey of U.S. employer-sponsored health plans, are as follows:

2020	5.50 %
2021	5.30
2022-2023	5.20
2024–2025	5.10
2026–2028	5.00
2029–2030	4.90
2031–2032	4.80
2033–2036	Reduce by 0.1 %
	every two years
2037 and thereafter	4.50

Changes in assumed healthcare cost trend rates may impact the amounts reported for postretirement healthcare benefits. A 1% increase in the healthcare cost trend rate would increase the APBO by approximately \$42,000 and increase interest and service cost by approximately \$2,000. A 1% decrease in the healthcare cost trend rate would decrease the APBO by approximately \$41,000 and reduce interest and service cost by approximately \$2,000.

Future benefit payments (in thousands) are expected to be paid as follows:

Payable in fiscal year:	
2020	\$ 961
2021	792
2022	547
2023	87
2024	2
2025–2029	2

(b) Defined Contribution Savings Plan

The System sponsors a defined-contribution savings plan, which covers substantially all of its employees. Total matching contributions made and accrued under the savings plan totaled approximately \$11.5 million and \$9.8 million for the years ended December 31, 2019 and 2018, respectively.

Beginning January 1, 2009, the deferred retirement savings program changed from the previous 403(b) plan sponsored by the Authority to a 401(k) Plan sponsored by the System. The System matches employee contributions dollar for dollar up to 4% of eligible employees' base compensation after completion of one year of eligible service. Employees are immediately fully vested in matching contributions.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(13) Leases

As previously described in note 1, the Agreement was determined to be a capital lease obligation under relevant accounting literature. Additionally, the System has also entered into certain other noncancelable medical equipment leases, determined to be capital lease obligations under relevant accounting literature, which expire at various dates through 2024.

Future minimum payments under these capital lease obligations at December 31, 2019 are as follows (in thousands):

		The	
	A	greement	Other
Payable in fiscal year:			
2020	\$	2,500	742
2021		2,500	735
2022		2,500	661
2023		2,500	524
2024		2,500	195
Thereafter		58,542	
		71,042	2,857
Less:			
Interest cost		(40,118)	(347)
Current portion		(355)	(595)
	\$	30,569	1,915

The System has also entered into certain noncancelable leases for office space, determined to be operating leases under relevant accounting literature, which expire at various dates through 2033. Total rent expense recognized for the years ended December 31, 2019 and 2018 was approximately \$13.4 million and \$11.4 million, respectively, principally for building and equipment rentals, and is included in supplies and other expenses in the accompanying consolidated statements of operations.

Future minimum payments due under noncancelable operating leases as of December 31, 2019 are as follows (in thousands):

Payable in fiscal year:	
2020	\$ 6,140
2021	6,069
2022	6,133
2023	5,511
2024	4,606
Thereafter	 20,352
	\$ 48,811

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(14) Donor Restricted Net Assets

Donor restricted net assets as of December 31, 2019 and 2018 are restricted for the following purposes:

	December 31		
	2019	2018	
	(In thousands)		
Subject to expenditures for specific purposes			
Capital improvements	\$ 52,282	62,141	
Fund-raising and other programs	 9,704	13,808	
	61,986	75,949	
Subject to restriction in perpetuity	 22,842	19,900	
Total	\$ 84,828	95,849	

(15) Business and Credit Concentrations

The System grants credit to patients, substantially all of whom reside in the System's service area. The System does not require collateral or other security in extending credit to patients; however, it routinely obtains assignment of (or is otherwise entitled to receive) patients' benefits payable under their health insurance programs, plans, or policies (e.g., Medicare, Medicaid, preferred provider arrangements, and commercial insurance policies).

The composition of patient accounts receivable, net by payor type is as follows:

	December 31	
	2019	2018
Medicare	19 %	23 %
Medicaid	28	30
Commercial and other third-party payors	49	44
Patients	4	3
	100 %	100 %

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(16) Fair Value of Financial Instruments

The System's estimates of fair value for financial assets and liabilities are based on the framework established in ASC 820, *Fair Value Measurement*, which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This framework is based on the inputs used in valuation and gives the highest priority to quoted prices in active markets and requires observable inputs to be used in the valuations when available. The disclosure of fair value estimates in the ASC 820 hierarchy is based on whether the significant inputs into the valuation are observable. In determining the level of the hierarchy in which the estimate is disclosed, the highest priority is given to unadjusted quoted prices in active markets and the lowest priority to unobservable inputs that reflect the System's significant market assumptions. The three levels of hierarchy are as follows:

Level 1 – Valuations based on unadjusted quoted market prices for identical assets or liabilities in active markets

Level 2 – Valuations based on pricing inputs that are other than quoted prices in active markets, which are either directly or indirectly observable. Examples include quoted prices in active markets for underlying assets, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in an inactive market, or valuations based on models where significant inputs are observable or can be corroborated by observable market data

Level 3 – Valuations derived from other valuation methodologies, including pricing models, discounted cash flow models, and similar techniques. Level 3 valuations incorporate certain assumptions and projections that are not observable in the market, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

The hierarchy requires the use of observable market data when available. As required by ASC 820, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The fair value hierarchy of the System's assets limited as to use is disclosed at note 4. Fair value disclosures under ASC 820 of the System's remaining financial instruments are as follows:

(a) Cash and Cash Equivalents

Cash and cash equivalents include short-term financial instruments whose carrying values approximate fair value, classified as Level 1 within the fair value hierarchy, given short-term maturity of these instruments.

(b) Beneficial Interest in Net Assets Held by Others

The carrying value of the System's beneficial interest in funds held by the Authority is adjusted annually for changes in fair value. The fair value of these funds is included in beneficial interest in net assets held by others in the accompanying consolidated balance sheets as of December 31, 2019 and 2018 at \$22.8 million and \$19.9 million, respectively. The remaining balance of \$1.9 million at both December 31, 2019, and 2018, included in beneficial interest in net assets held by others represents investments held by HSOC, Inc. (note 18(a)), which are also adjusted annually for changes in fair value.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

The majority of the related assets are investments in listed fixed income and equity securities, which are classified as Level 1 within the fair value hierarchy. The following is a summary of the fair value hierarchy for deposits and investments of the System's beneficial interest in funds held by the Authority and HSOC, Inc. as of December 31, 2019 and 2018, respectively (in thousands):

	2019						
	Level 1	Level 2	Level 3	Total			
Cash and cash							
equivalents	\$ 1,540	_	_	1,540			
U.S. money market							
funds	37	_	_	37			
U.S. equity securities	1,642	_	_	1,642			
U.S. mutual funds	15,425	_	_	15,425			
Real estate exchange							
traded funds	187	_	-	187			
International private							
equity funds	 		5,920	5,920			
	\$ 18,831		5,920	24,751			

			20 ⁻	18	
	_	Level 1	Level 2	Level 3	Total
Cash and cash					
equivalents	\$	1,539	_	_	1,539
U.S. money market					
funds		83	_	_	83
U.S. equity securities		1,187	_	_	1,187
U.S. mutual funds		13,714	_	_	13,714
Real estate exchange					
traded funds		235	_	_	235
International private					
equity funds				5,051	5,051
	\$	16,758		5,051	21,809

(c) Pledges Receivable, Net

Pledges receivable for current year gifts are initially measured at fair value in the year the receivable is recorded based on the present value of future cash flows discounted at a rate commensurate with the risks involved, which is an application of the income approach and are classified as Level 3 within the fair value hierarchy. Current year gifts included in pledges receivable reflected at fair value at December 31, 2019 and 2018 totaled approximately \$4.9 million and \$18.3 million, respectively.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(d) Patient Accounts and Grants Receivable, Accounts Payable, Due to Medical Schools, and Other Accrued Expenses

The carrying amounts of patient accounts and grants receivable, accounts payable, due to medical schools and other accrued expenses approximate fair value and are classified as Level 1 within the fair value hierarchy, because of the short-term maturity of these instruments.

(17) Affiliation with Medical Schools

Grady Memorial Hospital serves as the largest teaching hospital in the state of Georgia. In that respect, the System has contracts with Emory University School of Medicine (Emory) and Morehouse School of Medicine (Morehouse) (collectively, the Medical Schools), wherein practicing interns and residents of Emory and Morehouse receive clinical training at Grady Memorial Hospital. The teaching services provided to the interns and residents are provided primarily by faculty members of the Medical Schools in addition to other clinical and administrative services, which they provide to Grady Memorial Hospital. The Medical Schools are compensated for the costs of interns and residents effectively at cost. The Medical Schools are compensated for the faculty teaching, administrative, and clinical services based on certain formulas that consider the number of interns and residents instructed, time spent performing administrative services and otherwise unreimbursed clinical services, and consider fair market value of compensation rates by specialty and ranking. Additionally, the System has agreed to fund other costs specifically associated with the ongoing provision of physician services by the Medical Schools, including the cost of professional liability exposures and the funding of intergovernmental transfers to enable the receipt of related Medicaid program supplemental payments for physician services billed by the Medical Schools. The System's contracts with the Medical Schools expire on June 30, 2024. Net expenses for direct physician services under these contracts totaled approximately \$194.3 million and \$176.5 million for the years ended December 31, 2019 and 2018, respectively, and are included in supplies and other expenses in the accompanying consolidated statements of operations. Total amounts payable for direct physician services under these contracts totaled approximately \$26.3 million and \$19.7 million as of December 31, 2019 and 2018, respectively, and are included in due to Medical Schools in the accompanying consolidated balance sheets.

(18) Related-Party Transactions

(a) HSOC, Inc.

With the execution of the Agreement (note 1), HSOC, Inc. (HSOC) committed to a total of \$15 million of donated capital for capital improvements to Hughes Spalding. The System has a contract with HSOC, a nonprofit affiliate of Children's Healthcare of Atlanta (CHOA), whereby HSOC provides certain management, administrative, and related services to Hughes Spalding for an initial term of 15 years beginning in February 2006. This agreement may be renewed for an additional 10 years at the election of HSOC. The contract requires that Hughes Spalding operate under the name "Children's Healthcare of Atlanta at Hughes Spalding." HSOC is responsible for the costs of operating Hughes Spalding. Up until December 31, 2016, the System had a commitment of \$2 million of specific annual support for the operation of Hughes Spalding and CHOA had a matching support commitment of \$2 million annually. Additionally, the System was responsible for 50% of the Hughes Spalding "Excess/Deficit" (as defined) up to a total of \$2 million annually, not to exceed \$4 million in any successive rolling three-year period.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

The System entered into an amendment to the contract with HSOC effective January 1, 2017, which modifies certain terms and conditions included in the original contract. Under the terms of the amended contract, HSOC is responsible for all operating cash losses of Hughes Spalding (excluding depreciation and the operating impact of in-kind clinical services provided by the System), as well as the funding of all capital investments during the term of the contract. As a result, the System is no longer responsible for any annual operating support payments nor the funding of any Hughes Spalding "Excess/Deficit" (as defined). The amended contract also requires the System to maintain certain professional services relationships with the Medical Schools.

The System maintains ownership of Hughes Spalding, including ownership of Hughes Spalding's certificate of need, licensure, and provider agreements. The System had amounts due from HSOC totaling approximately \$0.6 million and \$0.7 million as of December 31, 2019 and 2018, respectively. Amounts due from HSOC are included in other current assets in the accompanying consolidated balance sheets. Hughes Spalding also had amounts due from HSOC totaling approximately \$17.7 million and \$2.6 million as of December 31, 2019 and 2018, respectively. Amounts due from HSOC are included in other current assets in the accompanying consolidated balance sheets.

The contract also gives CHOA the right to acquire Hughes Spalding, subject to a lease/purchase negotiation with the System and other terms and conditions. Any such option, if elected, contemplates a reversionary interest on the part of the System and other System involvement in HSOC's potential ownership of Hughes Spalding, which would be subject to additional negotiation as well. The contract also contemplates that, given the \$15 million in original donations by HSOC and other ongoing consideration under the agreement as described above, there would be no further economic consideration required in the exercise of the HSOC option. Given the significant uncertainties associated with the potential future exercise of the HSOC option, there is no current recognition of the option in the System's consolidated financial statements.

(b) Fulton-DeKalb Hospital Authority

During both the years ended December 31, 2019 and 2018, \$2.5 million of lease payments were provided to the Authority in accordance with the Agreement (note 1). On August 17, 2012, the System and the Authority entered into an agreement whereby the Authority will fund a minimum of \$0.7 million annually towards its pension obligation, as defined in the agreement. At the conclusion of the "lease years" ended May 31, 2019 and 2018, no excess funds were applied toward the Authority's pension obligation. As of December 31, 2019 and 2018, no amounts were due to the Authority under the System's annual funding obligation.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(19) Liquidity and Funds Available

The following table reflects the System's financial assets as of December 31, 2019, reduced by amounts not available for expenditure within one year. Financial assets considered unavailable include financial assets that are illiquid or not convertible to cash within one year, financial assets that are donor-restricted, and financial assets that the governing board has set aside for specific contingency reserves and projects, or for long-term investment as Board designated endowments.

	 2019	2018		
	(In thousands)			
Cash and cash equivalents	\$ 222,378	181,150		
Net patient accounts receivable	163,840	155,081		
Grants receivable	15,133	18,983		
Insurance proceeds receivable	10,021	_		
Other receivables	 42,894	29,333		
Financial assets available to meet cash needs for				
general expenditures within one year	\$ 454,266	384,547		

The Foundation is substantially supported by contributions. As a result of its current capital campaign, the majority of its contributions are restricted. Because a donor's restriction requires resources to be used in a particular manner or in a future period, the Foundation must maintain sufficient resources to meet those responsibilities to donors. Therefore, certain financial assets may not be available for general expenditures within one year.

As part of the System's liquidity management, it has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. The System invests cash in excess of daily requirements in money market funds, fixed income securities, and mutual funds.

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

(20) Lines of Credit

During February 2016, the System negotiated a new line-of-credit facility for \$30 million as a general revolving working capital facility. Since its initial expiration in February 2017, the System has renewed and maintained this line-of-credit at the same terms on an annual basis. Amounts outstanding under this facility currently accrue interest at one-month LIBOR plus 100 basis points. This facility carries a 10-basis point commitment fee on the unused line. No amounts were due under these lines of credit at both December 31, 2019 and 2018. Subsequent to December 31, 2019, the line of credit was renewed at substantially the same terms, expiring in March 2021. On April 6, 2020, \$30 million dollars was borrowed against the line to provide additional cash flow available to the System due to COVID-19 uncertainties.

(21) Functional Expenses

The System provides healthcare services to residents within its geographic location. Expenses related to providing these services on a functional basis were as follows for the years ended December 31, 2019 and 2018:

			20	19	
	_		Management		_
		Program	and		
		Services	General	Fundraising	Total
	_	_	(In thou	ısands)	
Salaries and benefits	\$	438,696	144,961	67	583,724
Supplies and other					
expenses		585,241	90,252	465	675,958
Interest		2,403	1,727	_	4,130
Depreciation and					
amortization		42,002	19,494		61,496
	\$_	1,068,342	256,434	532	1,325,308

			20	18				
			Management					
		Program	and					
		Services	General	Fundraising	Total			
			(In thou	ısands)				
Salaries and benefits	\$	405,820	137,583	61	543,464			
Supplies and other								
expenses		548,943	81,921	1,035	631,899			
Interest		2,424	1,652	_	4,076			
Depreciation and								
amortization	_	38,910	18,044		56,954			
	\$_	996,097	239,200	1,096	1,236,393			

Notes to Consolidated Financial Statements

December 31, 2019 and 2018

Certain costs have been allocated among the functional categories benefitted. Expenses related to executive salaries and benefits have been allocated based on an estimate of time and effort. Expenses associated with occupying and maintaining system facilities have been allocated based on a study of usage. Other allocated expenses are based on an overhead analysis consistent with the system's cost reporting methodology.

(22) U.S. Department of Education Financial Responsibility Standards Information

The System participates in federal Title IV student financial assistance programs, which require it to meet standards of financial responsibility based on criteria determined by the U.S. Department of Education (ED), as set forth in 34 CFR 668.171. The criteria include the annual calculation by ED of a financial responsibility composite score, as further outlined in 34 CFR 668.172, using audited financial statements submitted through ED's eZ-Audit system. The composite score has been and will continue to be based on three ratios: Primary Reserve, Equity, and Net Income. These ratios utilize the following financial data of the System, which are not otherwise presented in the consolidated financial statements or other notes to the consolidated financial statements, as of and for the year ended December 31, 2019:

Goodwill totaling \$0.147 million is included in other assets in the accompanying 2019 consolidated balance sheet.

Notes payable, net, new market tax credit totaling \$21.5 million and \$30.1 million at December 31, 2019 were issued on August 16, 2017 and April 17, 2015, respectively. The proceeds from the notes payable were used to fund capital assets in the accompanying 2019 consolidated balance sheet totaling \$21.9 million and \$80.8, respectively. The funded capital assets consist principally of capital projects associated with Emergency Department renovation and expansion and renovation of the Women's and Infant's Center.

Consolidating Schedule - Balance Sheet Information

December 31, 2019

(In thousands)

Assets	GN	мнс	Foundation	GHRI	GWIC	Reliant	Eliminations	Consolidated
Current assets:								
Cash and cash equivalents	\$ 2	15,466	5,645	_	1,047	220	_	222,378
Patient accounts receivable, net		63,840	-	_		_	_	163,840
Grants receivable, net		15,133	_	_	_	_	_	15,133
Insurance proceeds receivable		10,021	_	_	_	_	_	10,021
Current portion of pledges receivable		6,244	10,249	_	_	_	_	16,493
Other current assets		84,312	202	5,089	1,547	65	(11,397)	79,818
Total current assets	4	95,016	16,096	5,089	2,594	285	(11,397)	507,683
Assets limited as to use		15,290	32,562	519	933	_	_	49,304
Property and equipment, net		16,030	244	80,845	21,933	72		419,124
Notes receivable, new market tax credit		37,024	_	_	_	_	_	37,024
Beneficial interest in net assets held by others	:	24,751	_	_	_	_	_	24,751
Pledges receivable, net, excluding current portion		_	10,399	_	_	_	_	10,399
Investments in affiliates	1	13,391	_	_	_	_	(113,391)	_
Other assets		1,872						1,872
Total assets	\$ 1,0	03,374	59,301	86,453	25,460	357	(124,788)	1,050,157
Liabilities and Net Assets								
Current liabilities:								
Current portion of capital lease obligations	\$	950	_	_	_	_	_	950
Accounts payable		50,739	1,314	3,550	258	1,034	(11,293)	45,602
Current portion of self-insurance reserves		12,462	_	_	_	_		12,462
Due to third-party payors, net		25,491	_	_	_	_	_	25,491
Due to Medical Schools		26,313	_	_	_	_	_	26,313
Other accrued expenses		92,802			21		(104)	92,719
Total current liabilities	2	208,757	1,314	3,550	279	1,034	(11,397)	203,537
Capital lease obligations, excluding current portion	:	32,484	_	_	_	_	_	32,484
Notes payable, net, new market tax credit		_	_	30,128	21,534	_	_	51,662
Self-insurance reserves, excluding current portion	:	39,897	_	_	_	_	_	39,897
Accrued postretirement benefit cost		1,358	_	_	_	_	_	1,358
Other long-term liabilities		6,995	341					7,336
Total liabilities	2	289,491	1,655	33,678	21,813	1,034	(11,397)	336,274
Net assets (deficit):								
Without donor restrictions	6	29,056	3,861	52,775	3,647	(677)	(59,607)	629,055
With donor restrictions		84,827	53,785	_	_	`	(53,784)	84,828
Total net assets (deficit)	7	13,883	57,646	52,775	3,647	(677)	(113,391)	713,883
Commitments and contingencies								
Total liabilities and net assets (deficit)	\$ 1,0	03,374	59,301	86,453	25,460	357	(124,788)	1,050,157

See accompanying independent auditors' report.

Consolidating Schedule - Statement of Operations Information

Year ended December 31, 2019

(In thousands)

		эмнс	Foundation	GHRI	GWIC	Reliant	Eliminations	Consolidated
Revenue, gains, and other support:								
Net patient service revenue	\$ 1,	,156,566	_	_	_	_	_	1,156,566
Contributions from Fulton and DeKalb Counties		55,435	_	_	_	_	_	55,435
Grant revenue		64,170	_	_	_	_	_	64,170
Other revenue		71,197	6,877			406	(4,223)	74,257
Total revenue, gains, and other support	1,	,347,368	6,877			406	(4,223)	1,350,428
Operating expenses:								
Salaries and benefits		582,467	3,100	_	_	62	(1,905)	583,724
Supplies and other expenses		679,234	1,898	_	_	388	(2,318)	679,202
Insurance proceeds from flood losses		(3,244)	_	_	_	_	_	(3,244)
Interest		4,127	_	_	_	3	_	4,130
Depreciation and amortization		61,443	28			25		61,496
Total operating expenses	1,	,324,027	5,026			478	(4,223)	1,325,308
Operating income (loss)		23,341	1,851			(72)		25,120
Nonoperating gains (losses), net:								
Investment income, net		3,873	_	_	_	_	_	3,873
Net periodic postretirement benefit credit		1,144	_	_	_	_	_	1,144
New market tax credit, net		(635)	_	252	(62)	_	_	(445)
Equity in gains (losses) of affiliates		1,969	_	_	_	_	(1,969)	_
Other		84						84
Total nonoperating gains (losses), net		6,435		252	(62)		(1,969)	4,656
Revenue, gains, and other support in excess of (less than) expenses and losses		29,776	1,851	252	(62)	(72)	(1,969)	29,776
Accrued postretirement benefit cost adjustments		(535)	_	_	_	_	_	(535)
Net assets released from restriction used for the purchase of property and equipment		18,975	_	_	_	_	_	18,975
Contributions and other		2,750						2,750
Change in net assets without donor restrictions	\$	50,966	1,851	252	(62)	(72)	(1,969)	50,966

See accompanying independent auditors' report.

Schedule 3

GRADY MEMORIAL HOSPITAL CORPORATION AND AFFILIATES

Financial Responsibility Supplemental Schedule

Year ended December 31, 2019

(In thousands)

Deimony, recoming resting			
Primary reserve ratio: Expendable net assets:			
Consolidated balance sheet	Net assets without donor restrictions	\$	629,055
Consolidated balance sheet	Net assets with donor restrictions	Ψ	84,828
Notes to consolidated financial statements –	Not addete with denot redirections		04,020
Note (14) – donor restricted net assets	Net assets with donor restrictions –		
subject to restriction in perpetuity	restricted in perpetuity		22,842
Notes to consolidated financial statements –	roomerou in perperanty		,0
Note (22) – goodwill	Goodwill		147
Consolidated balance sheet	Property and equipment, net		419,124
Consolidated balance sheet	Notes payable, net, new market tax credit		51,662
Notes to consolidated financial statements –	, , ,		,
Note (8) – current portion of accrued			
postretirement benefit cost	Post-employment liabilities		961
Consolidated balance sheet – accrued			
postretirement benefit cost	Post-employment liabilities		1,358
Total expenses:			
Consolidated statement of operations –			
total operating expenses	Total expenses without donor restrictions		1,325,308
Equity rotio:			
Equity ratio: Modified net assets:			
Consolidated balance sheet	Net assets without donor restrictions	\$	629,055
Consolidated balance sheet	Net assets with donor restrictions	Ψ	84,828
Notes to consolidated financial statements –	Not assets with donor restrictions		04,020
Note (22) – goodwill	Goodwill		147
Modified assets:	Codawiii		1-77
Consolidated balance sheet	Total assets		1,050,157
Notes to consolidated financial statements –	. 5151. 455515		.,000,.0.
Note (22) – goodwill	Goodwill		147
, , <u>,</u>			
Net income ratio:			
Change in net assets without donor restrictions:	Observation of the Alberta		
Consolidated statement of operations	Change in net assets without donor	Φ.	F0 000
Total rayanua without danar restrictions and	restrictions	\$	50,966
Total revenue without donor restrictions and gains without donor restrictions:			
<u> </u>	Total revenue, going and other augment		1,350,428
Consolidated statement of operations Consolidated statement of operations	Total revenue, gains and other support Investment income, net		3,873
Consolidated statement of operations	Net periodic postretirement benefit credit		1,144
Notes to consolidated financial statements –	Service cost component included in net		1,144
Note (12(a)) – service cost	periodic postretirement benefit credit		32
Consolidated statement of changes in net	Net assets released from restriction used for		02
assets	the purchase of property and equipment		18,975
Consolidated statement of changes in net	s paranass s. proporty and oquipmont		.0,0.0
assets	Contributions and other		2,750
			,

See accompanying independent auditors' report.



KPMG LLP Suite 2000 303 Peachtree Street, N.E. Atlanta, GA 30308-3210

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

To the Board of Directors
Grady Memorial Hospital Corporation:

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Grady Memorial Hospital Corporation and affiliates (the System), which comprise the consolidated balance sheet as of December 31, 2019, and the related consolidated statements of operations, changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated April 28, 2020, except as to note 22 and our report on the financial responsibility schedule, which are as of September 22, 2020. Our report refers to the System's implementation of Financial Accounting Standards Board Accounting Standards Update No. 2014-09, *Revenue from Contracts with Customers* during 2019. The financial statements of Henry W. Grady Health System Foundation, Inc., were not audited in accordance with *Government Auditing Standards*, and accordingly, this report does not include reporting on internal control over financial reporting or instances of reportable noncompliance associated with the Henry W. Grady Health System Foundation, Inc.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the System's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the System's internal control. Accordingly, we do not express an opinion on the effectiveness of the System's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



Compliance and Other Matters

As part of obtaining reasonable assurance about whether the System's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the System's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the System's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Atlanta, Georgia April 28, 2020, except as to note 22 and our report on the financial responsibility schedule, which are as of September 22, 2020.

Information Required Under the Single Audit Act and Office of Management and Budget's Uniform Guidance For the Year Ended December 31, 2019 (With Independent Auditor's Reports Thereon)

December 31, 2019

Table of Contents

	<u>Page</u>
OMB Uniform Guidance	
Schedule of Findings and Questioned Costs - Summary of Auditor's Results	2
Independent Auditor's Report on Compliance for Each Major Program And on Internal Control Over Compliance Required by the Uniform Guidance	4
Schedule of Findings and Questioned Costs	6
Schedule of Federal and State Contractual Assistance	9
Notes to the Schedule of Federal and State Contractual Assistance	16
Status of Prior Audit Findings and Questioned Costs	20

Schedule of Findings and Questioned Costs Year Ended December 31, 2019

Section I – Summary of Auditor's Results

On May 20, 2008, The Fulton-DeKalb Hospital Authority (the "Authority") entered into a lease and transfer agreement with the Grady Memorial Hospital Corporation (GMHC), a non-profit corporation organized under the laws of the State of Georgia, to lease the Authority's health system facilities. The agreement transfers the operating assets and existing operations, as well as the performance and discharge of all other obligations for consideration of annual rent of \$2,500,000. The Authority assigns, transfers, and conveys right, title, and interest in and to all assets to the GMHC. The entities are collectively referred to in this report as the "Hospital".

This report has been previously submitted under the name The Fulton-DeKalb Hospital Authority; however, pursuant to the above paragraph, it is now submitted under the name Grady Memorial Hospital Corporation.

FinancialStatements

The audits of the basic financial statements of the GMHC were performed by other auditors. The report by the auditor of the GMHC on financial statements as of and for the year then ended December 31, 2019, dated April 29, 2020, expressed an unmodified opinion on those statements.

In connection with the audit of the basic financial statements of the GMHC, the other auditors did not disclosed any significant deficiencies and no material weaknesses which are disclosed in their report issued under separate cover and dated April 29, 2020.

FederalAwards

We issued an unmodified opinion on the compliance for major programs for the Hospital for the year ended December 31, 2019.

We noted no significant deficiencies or material weaknesses involving the internal control over major programs.

We noted no findings that we are required to report in accordance with the Uniform Guidance, Section 200.516.

<u>IdentificationofMajorPrograms</u>:

The following programs were audited as major programs:

Name of Federal Programor Cluster	CFDA Number
Ryan White Part A	93.914
Poison Center Support and Enforcement	93.253

We used a threshold of \$750,000 expended to distinguish between Type A and Type B programs.

The Hospital is considered a low-risk auditee.

Section II – Current Year Financial Statement Findings

No findings in the current year.



INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE FOR EACH MAJOR PROGRAM AND ON INTERNAL CONTROL OVER COMPLIANCE REQUIRED BY THE UNIFORM GUIDANCE

To the Board of Trustees
The Fulton-DeKalb Hospital Authority

The Board of Directors Grady Memorial Hospital Corporation

Report on Compliance for Each Major Federal Program

We have audited The Fulton-DeKalb Hospital Authority d/b/a Grady Health System (the "Hospital")'s compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of the Hospital's major federal programs for the year ended December 31, 2019. The Hospital's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for each of the Hospital's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the Hospital's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Hospital's compliance.

Opinion on Each Major Federal Program

In our opinion, the Hospital's complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended December 31, 2019.

3504 EAST MAIN STREET • COLLEGE PARK, GEORGIA 30337 • (404) 763-1002



To the Board of Trustees The Fulton-DeKalb Hospital Authority

The Board of Directors Grady Memorial Hospital Corporation Page 2

Report on Internal Control over Compliance

Management of the Hospital is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the Hospital's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the Hospital's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Bank, Finley White & Co.

College Park, GA September 30, 2020

December 31, 2019

Section III - Current Year Federal Award Findings and Questioned Costs

None identified.



INDEPENDENT AUDITOR'S REPORT

'To the Board of Trustees The Fulton-DeKalb Hospital Authority

The Board of Directors Grady Memorial Hospital Corporation

Report on the Schedule of Expenditures of Federal Awards

We have audited the accompanying Schedule of Federal and State Contractual Assistance of The Fulton-DeKalb Hospital Authority d/b/a Grady Health System for the year ended December 31, 2019, and the related notes (the "Schedule")

Management's Responsibility

Management is responsible for the preparation and fair presentation of this financial statement in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of a financial statement that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on this financial statement based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statement.

3504 EAST MAIN STREET • COLLEGE PARK, GEORGIA 30337 • (404) 763-1002



To the Board of Trustees The Fulton-DeKalb Hospital Authority

The Board of Directors Grady Memorial Hospital Corporation Page 2

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statement referred to above presents fairly, in all material respects, the expenditures of federal awards of The Fulton-DeKalb Hospital Authority d/b/a Grady Health System for the year ended December 31, 2019, in accordance with accounting principles generally accepted in the United States of America. Banks, Finley White & Co.

College Park, GA September 30, 2020

Schedule of Federal and State Contractual Assistance

Federal Grantor/Pass-Through Grantor/Program Title	CEDA_ Number	Grantor's Number	Award or Amount	Program Revenues	Expenditures to Subrecipients	Total Expenditures
U.S. Department of Health and Human Services Passed through the Georgia Department of Behavioral Health: and Developmental Disabilities						
Fiscal 2019	93.958	44100-263-0262019033	5,718,955.00	2,859,475.00		2,859,475.00
Fiscal 2020 Subtotal	93.958	44100-263-0262020033	5,718,955.00 11,437,910.00	2,859,483.00 5,718,958.00	0.00	2,859,480.00 5,718,955.00
			11,437,510.00	3,710,930.00	0.00	3,710,933.00
93.150 Projects for Assistance in Transition from Homelessness (PATH)						
Fiscal 2019	93.15	44100-263-0262019033	174,363.00	84,222.00		84,222.00
Fiscal 2020	93.15	44100-263-0262020033	174,363.00 348,726.00	86,025.00 170,247.00		86,025.00 170,247.00
			348,726.00	170,247.00	0.00	170,247.00
PSY - Light Early Treatment Program						
Fiscal 2019	93.958	44100-026-0000123182	285,020.00	117,333.00		117,608.00
Fiscal 2020	93.958	44100-026-0000123182	275,294.00 560,314.00	59,279.00 176,612.00		59,004.00 176,612.00
U.S. Donostonos of World and Harris Services		_	,	,		,
U.S. Department of Health and Human Services						
Medication Assisted Treatment						
Fiscal 2019	93.788	44100-906-0000111396	215,000.00	99,232.00		110,851.00
Fiscal 2020	93.788	44100-906-0000127982	305,000.00 520,000.00	197,671.00 296,903.00		197,671.00 308,522.00
U.S. Department of Health and Human Services HIV Care and Emergency Relief Formula Grants Passed through the Georgia Department of Community Health AIDS State Clinic:						
Fiscal 2019	93.914	40500-044-19161557	4,806,981.00	2,757,797.00		2,823,678.00
Fiscal 2020 Subtotal	93.914	40500-044-20161557	4,738,605.00 9,545,586.00	1,946,265.00 4,704,054.00		2,032,922.00 4,856,600.00
U.S. Department of Health and Human Services *Ryan White Care Act: Passed through Fulton County:		-	9,343,386.00	4,704,004.00		4,830,000.00
Ryan White Part A						
Fiscal 2019	93.914	PO-118-185-C112744B-RD	10,061,321.00	1,330,328.00		1,770,102.00
Fiscal 2020 Subtotal	93.914	PO-19 I75CI 028658-BR	9,561,321.00 19,622,642.00	7,701,047.00 9,031,375.00		7,317,154.00 9,087,256.00
U.S. Department of Health and Human Services		-	25,022,042.00	-,,		3,001,230.00
Ryan White Care Act Direct Program						
Ryan White (Part D):\\ and HIV OB						
	93.153	6HI2HA24799-07-01		51,876.34		47,950.97
Fiscal 2019	93.153	6HI2HA24799-07-01	829,484.00	328,257.33	55,211.10	472,546.90
	93.153	6HI2HA24799-08-01		23,940.34		27,865.72
Fiscal 2020	93.153	6HI2HA24799-08-01	775,657.00 1,605,141.00	398,775.62 802,850.00		254,486.00 802,849.59
		-		,	,	
Dissemination of Evidence-Informed Interventions (AID		190001130330	100 017 07	422.000		437.240.77
Fiscal 2019 Fiscal 2020	93.928 93.928	U90HA29370401 U90HA29370401	199,817.00 30,000.00	127,650.92 621.00		127,310.77 621.00
			229,817.00	128,271.92		127,931.77

Schedule of Federal and State Contractual Assistance

	CFDA		Award or		Europe diturne to	Total
Federal Grantor/Pass-Through Grantor/Program Title	Number	Grantor's Number	Amount	Program Revenues	Expenditures to Subrecipients	Expenditures
				_		
U.S. Department of Health and Human Services Primary Care Training and Enhancement						
Fiscal 2019	93.884	T0BHP299950301	600,000.00	412,976.12	249,552.00	410,991.60
Fiscal 2020	93.884	T0BHP299950401	500,000.00	111,657.57	0.00	113,642.10
		_	1,100,000.00	524,634.00	249,552.00	524,633.69
Maternal and Child Health Services Block Grants:						
Passed through the Georgia Department of Community Health	ı					
Sickle Cell Legislative:						
Fiscal 2019	93,994	40500-043-19161576	1,726,542.00	820,547.85	176,781.89	820,547.95
Fiscal 2020	93.994	40500-043-20161576	1,701,984.00 3,428,526.00	810,725.43 1,631,273.00	100,779.52 277,561.41	810,725.34 1,631,273.29
		_	3,428,320.00	1,031,273.00	277,301.41	1,031,273.29
Neonatal Intensive Infant Care: Fiscal 2019	93.994	40500-039-19182475	579,739.00	0.00		0.00
Fiscal 2020	93.994	40500-039-20182475	577,651.00	577,651.04		577,650.61
			1,157,390.00	577,651.00		577,650.61
						_
Maternal and Infant Care:						
Fiscal 2019	93.994	40500-039-19182474	980,034.00	419,252.64		419,252.64
Fiscal 2020	93.994	40500-039-20182474	847,336.00	521,964.34		521,964.33
Subtotal		_	1,827,370.00	941,217.00		941,216.97
Poison Control Stabilization and Enhancement (Federal)						
Fiscal 2019	93.253	5H4BHS15495-10-01	568,326.00	487,883.28		535,930.04
Fiscal 2020	93.253	5H4BHS15495-11-00	627,060.00	83,834.55		35,787.75
Subtotal		_	1,195,386.00	571,718.00		571,717.79
Poison Control Center (State): Fiscal 2019	93.253	40500-036-19161634	3 901 006 00	1 242 575 45		1 242 575 45
Fiscal 2019	93.253	40500-036-20161634	3,801,906.00 3,750,751.00	1,343,575.45 2,562,138.66		1,343,575.45 2,562,138.66
Total Editor	33.23	40300 030 2020334	7,552,657.00	3,905,717.00		3,905,714.11
Training Courses for Georgia Healthcare Providers Fiscal 2019	93.889	40500-033-18182449	62,800.00	0.00		0.00
Poison Control (State) - BT Hotline						
Fiscal 2019	93.069	40500-033-19151254	197,200.00	52,850.00		90,600.00
Fiscal 2020	93.069	40500-036-20203135	197,200.00	128,350.00		90,600.00
		_	394,400.00	181,200.00		181,200.00
Pass through the 'Family Health Centers of Georgia						
Family Planning Title X						
Fiscal 2019	93.217	FPHPA006481	527,645.00	225,707.00		225,707.00
Fiscal 2020	93.217	FPHPA006481	643,800.00	477,478.00		444,550.00
		-	1,171,445.00	703,185.00		670,257.00
Centers for Disease Control and Prevention						
Passed through Fulton County:						
High-Impact Comprehensive HIV Prevention HIV FOCUS Program						
-			205	4		******
Fiscal 2019	93.940	<u>\$201816</u>	305,000.00	49,569.52		49,570.00
Grady Rape Crisis Center - Part D						
Fiscal 2019	93.991	X19-8-069	48,933.00	41,390.00		40,431.72
Fiscal 2020	93.991	X20-8-005	48,933.00	21,065.00		22,023.00
		_	97,866.00	62,455.00		62,454.72

December 31, 2019

Schedule of Federal and State Contractual Assistance (Continued)

	CEDA				E	T-1-1
Federal Control Program Control Program Tale	<u>CFDA</u> Number	Grantor's Number	Award or Amount	D	Expenditures to Subrecipients	Total Expenditures
Federal Grantor/Pass-Through Grantor/Program Title	Ivumber	Grantor's Number	Amount	Program Revenues	Subrecipients	Expenditures
Rape Crisis VOCA						
Fiscal 2019	16.575 16.575	<u>C16-8-096</u> C18-8-289	350,628.00 331,550.00	100,972.18 37,495.12		100,972.10 37,495.20
	20.373	<u></u>	682,178.00	138,467.30		138,467.30
		_		,		,
Passed through the Georgia Department of Community Health	•					
Tuberculosis Detection: Fiscal 2019		40500 045 47454574	77 575 00	40.704.00		40.704.00
Fiscal 2020	93.116 93.116	40500-046-17151534 40500-046-19151534	77,576.00 77,576.00	19,394.00 58,182.00		19,394.00 58,182.00
Tibel 2020	33.220	40300 040 13131334	155,152.00	77,576.00		77,576.00
		_	•			
Cancer Control (BCCP)						
Fiscal 2019	93.283	40500-032-19161630	166,650.00	40,723.08		42,866.38
Fiscal 2020	93.283	40500-032-20161630	166,650.00 333,300.00	86,673.18 127,396.00		84,529.88 127,396.26
		-	333,300.00	127,550.00		127,550.20
Centers for Disease Control and Prevention						
Passed through National Association of County						
and City Health Officials						
EMS OPIOID Response						
Fiscal 2019	93.421	2019-010303	100,000.00	100,000.00		100,000.00
Fiscal 2020	93.421	2019-1212109	50,000.00			
		_	150,000.00	100,000.00		100,000.00
U.S. Department of Health and Human Services						
Georgia Alzheimer Project						
Pass through - Emory University Fiscal 2019	93.051	42700-373-0000083451	350,000.00	60,154.28		60,154.00
Fiscal 2020	93.051	42700-373-0000083451	337,270.00	69,420.42		69,421.00
			687,270.00	129,575.00		129,575.00
Total U.S. Department of Health and Human Services		_	64,170,876.00	30,750,904.74	596,330.98	30,937,676.10
U.S. Department of Agriculture						
Passed through the Georgia Department of Community Health:						
Special Supplemental Food Program for Women, Infants, and Children:						
WIC Supplemental Nutrition Program:						
Fiscal 2019	10.557	40500-041-19161824	404,757.00	291,417.00		291,417.10
Fiscal 2020	10.557	40500-041-20161824	404,757.00	97,050.00		97,048.32
Subtotal		_	809,514.00	388,467.00	0.00	388,465.42
WIC Supplemental Nutrition Program(Non Cash Vouchers)						
Fiscal 2018	10.557	40500-041-18161824	361,085.00	361,085.00		361,085.00
				,		,
Emory/Grady Urban Health Initiative Program						
Fiscal 2019	10.225	2014-33800-22390	599,078.00	262,114.05		262,114.00
			599,078.00	262,114.05	0.00	262,114.00
Uniformed Services University of the Health Sciencies						
Surgical Critical Care Iniitiative - Sti study						
Fiscal 2019	12.750	<u>T976130</u>	7,682.00	2,531.84		2,531.84
		-	7,682.00	2,532.00	_	2,531.84
		-	,,002.00	2,332.00	_	2,032.04

December 31, 2019

Schedule of Federal and State Contractual Assistance (Continued)

	CFDA		Award or		Expenditures to	Total
Federal Grantor/Pass-Through Grantor/Program Title	Number	Grantor's Number	Amount	Program Revenues	Subrecipients	Expenditures
Smart Policing Intiative (Gun Violence)						
Fiscal 2019	16.738	H16-8-002	339,705.00	51,179.48		48,739.00
Fiscal 2020	16.738	H16-8-002	339,705.00 679,410.00	18,773.68 69,953.00	_	10,446.63 59,185.63
		-	075,410.00	65,555.00	_	35,103.03
U.S. Department of Education						
Student Financial Assistance Programs: Pell Grants Radiologic Technology:						
rendrate Radiosge recinology.						
Fiscal 2019	84.063	P063P142499	182,620.00	157,601.00	0.00	157,601.00
US Department of Labor						
Workforce Investment Act (WIA)						
Atlanta Regional Commission - WIA	17.259	58-6000814	4,800.00	4,800.00		4,800.00
Georgia Department of Labor	17.259	58-6000814	3,300.00	3,300.00		3,300.00
DeKalb Workforce Development Center	17.259	58-6000814_	3,300.00 11,400.00	3,300.00 11,400.00	0.00	3,300.00 11,400.00
			11,400.00	11,400.00	0.00	11,400.00
National Institute of Health						
Passed through University of Miami						
All of Us Research						
Fiscal 2019	93.310	10T20D026551-01	140,326.00	85,537.00		85,537.00
		_				
Broad droved National Local Broads						
Passed through National Jewish Health						
COPD GENE STUDY						
Fiscal 2019	93.838	U01 HL89897-12	6,699,819.00	3,000.00		3,000.00
	93.838	U01 HL89897-12	6,699,819.00	3,000.00		3,000.00
Fiscal 2019	93.838				596 330 98	
	93.838	U01 HL89897-12 Subtotal Federal	6,699,819.00 73,661,810.00	3,000.00 32,092,593.79	596,330.98	3,000.00 32,268,595.99
Fiscal 2019 Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey		Subtotal Federal	73,661,810.00	32,092,593.79	596,330.98	32,268,595.99
Fiscal 2019 Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019	NA	Subtotal Federal CPSC-N-14-0059	73,661,810.00 164,647.00	32,092,593.79 78,956.13	596,330.98	32,268,595.99 78,956.13
Fiscal 2019 Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey		Subtotal Federal	73,661,810.00 164,647.00 235,159.00	32,092,593.79 78,956.13 119,236.18	596,330.98	32,268,595.99 78,956.13 119,236.20
Fiscal 2019 Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020	NA	Subtotal Federal CPSC-N-14-0059	73,661,810.00 164,647.00	32,092,593.79 78,956.13	596,330.98	32,268,595.99 78,956.13
Fiscal 2019 Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019	NA	Subtotal Federal CPSC-N-14-0059	73,661,810.00 164,647.00 235,159.00	32,092,593.79 78,956.13 119,236.18	596,330.98	32,268,595.99 78,956.13 119,236.20
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019	NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00	78,956.13 119,236.18 198,192.31 108,121.00	596,330.98	78,956.13 119,236.20 198,192.33
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis:	NA NA	Subtotal Federal <u>CPSC-N-14-0059</u> <u>CPSC-21131-20-0084</u>	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 216,242.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019	NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00	78,956.13 119,236.18 198,192.31 108,121.00	596,330.98	78,956.13 119,236.20 198,192.33
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019	NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 216,242.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020	NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 216,242.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020 Forensics Psychiatric Evaluation:	NA NA NA	CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586 40500-046-20161586	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 432,484.00 255,000.00 255,000.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00 216,240.00	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00 216,243.00 127,500.00 127,500.00
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020 Forensics Psychiatric Evaluation: Fiscal 2019	NA NA NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586 40500-046-20161586	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 216,242.00 432,484.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00 216,240.00	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00 216,243.00
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020 Forensics Psychiatric Evaluation: Fiscal 2019 Fiscal 2020	NA NA NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586 40500-046-20161586	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 432,484.00 255,000.00 255,000.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00 216,240.00	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00 216,243.00 127,500.00 127,500.00
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020 Forensics Psychiatric Evaluation: Fiscal 2019	NA NA NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586 40500-046-20161586 44100-026-0000111788 44100-016-00000130007	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 432,484.00 255,000.00 255,000.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00 216,240.00	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00 216,243.00 127,500.00 127,500.00
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020 Forensics Psychiatric Evaluation: Fiscal 2019 Fiscal 2020 Assertive Community Treatment (ACT) III	NA NA NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586 40500-046-20161586 44100-026-0000111788 44100-016-00000130007	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 216,242.00 432,484.00 255,000.00 255,000.00 780,000.00 780,000.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00 216,240.00 127,500.00 255,000.00	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00 216,243.00 127,500.00 255,000.00 536,968.92 266,256.83
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020 Forensics Psychiatric Evaluation: Fiscal 2019 Fiscal 2020 Assertive Community Treatment (ACT) III Fiscal 2019	NA NA NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586 40500-046-20161586 44100-026-0000111788 44100-016-00000130007	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 432,484.00 255,000.00 255,000.00 780,000.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00 216,240.00 127,500.00 127,500.00 255,000.00	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00 216,243.00 127,500.00 127,500.00 255,000.00
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020 Forensics Psychiatric Evaluation: Fiscal 2019 Fiscal 2020 Assertive Community Treatment (ACT) III Fiscal 2019	NA NA NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586 40500-046-20161586 44100-026-0000111788 44100-016-00000130007	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 216,242.00 432,484.00 255,000.00 255,000.00 780,000.00 780,000.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00 216,240.00 127,500.00 255,000.00	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00 216,243.00 127,500.00 255,000.00 536,968.92 266,256.83
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020 Forensics Psychiatric Evaluation: Fiscal 2019 Fiscal 2020 Assertive Community Treatment (ACT) III Fiscal 2019	NA NA NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586 40500-046-20161586 44100-026-0000111788 44100-016-00000130007	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 216,242.00 432,484.00 255,000.00 255,000.00 780,000.00 780,000.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00 216,240.00 127,500.00 255,000.00	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00 216,243.00 127,500.00 255,000.00 536,968.92 266,256.83
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020 Forensics Psychiatric Evaluation: Fiscal 2019 Fiscal 2020 Assertive Community Treatment (ACT) III Fiscal 2019 Fiscal 2020 Assertive Community Treatment (ACT) I and II Fiscal 2019	NA NA NA NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586 40500-046-20161586 44100-026-000011788 44100-26-0000130007 441000-26-0000139780 41100-026-0000139780	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 432,484.00 255,000.00 255,000.00 780,000.00 780,000.00 1,560,000.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00 216,240.00 127,500.00 255,000.00 536,968.60 266,256.82 803,225.42	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,122.00 216,243.00 127,500.00 225,000.00 536,968.92 266,256.83 803,225.75
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020 Forensics Psychiatric Evaluation: Fiscal 2020 Assertive Community Treatment (ACT) III Fiscal 2020 Assertive Community Treatment (ACT) I and II	NA NA NA NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586 40500-046-20161586 44100-026-0000111788 44100-016-00000130007 441000-26-0000120122 441000-26-0000139780	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 216,242.00 432,484.00 255,000.00 510,000.00 780,000.00 1,560,000.00 1,560,000.00 1,560,000.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00 216,240.00 127,500.00 127,500.00 255,000.00 536,968.60 266,256.82 803,225.42	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,121.00 216,243.00 127,500.00 127,500.00 255,000.00 536,968.92 266,256.83 803,225.75
Subtotal - FEDERAL Consumer Product Safety Commission NEISS Surveillance Report and Special Survey Fiscal 2019 Fiscal 2020 Georgia Department of Community Health Statewide Tuberculosis: Fiscal 2019 Fiscal 2020 Forensics Psychiatric Evaluation: Fiscal 2019 Fiscal 2020 Assertive Community Treatment (ACT) III Fiscal 2019 Fiscal 2020 Assertive Community Treatment (ACT) I and II Fiscal 2019	NA NA NA NA NA	Subtotal Federal CPSC-N-14-0059 CPSC-21131-20-0084 40500-046-19161586 40500-046-20161586 44100-026-000011788 44100-26-0000130007 441000-26-0000139780 41100-026-0000139780	73,661,810.00 164,647.00 235,159.00 399,806.00 216,242.00 432,484.00 255,000.00 255,000.00 780,000.00 780,000.00 1,560,000.00	78,956.13 119,236.18 198,192.31 108,121.00 108,119.00 216,240.00 127,500.00 255,000.00 536,968.60 266,256.82 803,225.42	596,330.98	78,956.13 119,236.20 198,192.33 108,122.00 108,122.00 216,243.00 127,500.00 225,000.00 536,968.92 266,256.83 803,225.75

Federal Grantor/Pass-Through Grantor/Program Title	<u>CFDA</u> <u>Number</u>	Grantor's Number	Award or Amount	_Program Revenues	Expenditures to Subrecipients	Total Expenditures
Case Management						
Fiscal 2019	NA	44100-026-0000112177	57,600.00	28,800.00		28,800.00
Fiscal 2020	NA	44100-026-0000131250	57,600.00	28,800.00		28,800.00
			115,200.00	57,600.00		57,600.00
New or Expanded Collection Hospital Development for Public						
Cord Blood Collection Fiscal 2019						
	NA	NMDP 213619	112,958.00	380,461.00		376,531.00
Fiscal 2020	NA	NMDP 508776	376,531.00 489,489.00	0.00 380,461.00	_	0.00 376,531.00
IDP NAVIGATOR						
Fiscal 2019	NA	40500-044-19172176	150,000.00	48,509.07		61,959.00
Fiscal 2020	NA	40500-044-20172176	150,000.00	92,852.50		79,402.83
			300,000.00	141,361.57		141,361.83
Trauma Readiness Services Fiscal 2019	NA	CTC C+-2010.3	2,784,269.00	1,810,644.38		1 105 007 50
Fiscal 2020	NA NA	GTC Grady2019.2 GTC Grady2020.1	2,784,269.00	974,320.50		1,106,887.50 1,700,757.00
FISCAL 2020	MA	GTC Grady2020.1	5,175,486.72	2,784,965.00	_	2,807,644.50
Trauma Readiness Services (Burn)			3,173,400.72	2,704,505.00		2,807,044.30
Fiscal 2019	NA	GTC GradyBurn2019.2	371,120.00	239,369.00		279,927.00
Fiscal 2020	NA	GTC GradyBurn2020.1	256,606.00	123,532.00		81,397.00
			627,726.00	362,901.00	_	361,324.00
Georgia Board for Physician Workforce						
Residency Capitation						
Fiscal 2019	Unknown	2015036	3,278,334.00	2,092,673.25		2,092,673.25
Fiscal 2020	Unknown	2015036	3,278,334.00	2,275,949.43	_	2,275,949.43
			6,556,668.00	4,368,622.68		4,368,622.68
Fulton County Board of Health Mental Health Ryan White A - Ryan White Early Intervention	NA	H89HA000007	66,568.00	10,540.00		11,094.58
wichter freeith kyan white A - kyan white carry intervention	NA NA	H89HA000007	66,568.00	56,028.00		55,473.00
	NA.	nasnauccou/	133,136.00	66,568.00	_	66,567.58
Fulton County Government Medication Assisted Treatment						
Fiscal 2019	N/A	None	464,534.00	464,533.00		464,533.00
Fiscal 2020	N/A	None	464,534.00			
			929,068.00	464,533.00		464,533.00
Sub Total - STATE			20,349,063.72	11,595,018.86	0.00	11,612,195.30
Grand Total		:	94,010,873.72	43,687,612.65	596,330.98	43,880,791.28

Notes to the Schedule of Federal and State Contractual Assistance December 31, 2019

1. General:

On May 20, 2008, The Fulton-DeKalb Hospital Authority (the "Authority") entered into a lease and transfer agreement with the Grady Memorial Hospital Corporation (GMHC), a non-profit corporation organized under the laws of the State of Georgia, to lease the Authority's health system facilities. The agreement transfers the operating assets and existing operations, as well as the performance and discharge of all other obligations for consideration of annual rent of \$2,500,000. The Authority assigned, transferred, and conveyed right, title, and interest in and to all assets to the GMHC.

The accompanying Schedule of Federal and State Contractual Assistance presents the combined activity of Federal and State assistance programs of the Authority and GMHC. Contractual assistance received directly from Federal grantor agencies, as well as contractual assistance passed through other government agencies, and direct state of Georgia contractual assistance are included on the accompanying schedule.

2. Accounting Principles:

- a. The schedule of expenditures of federal awards includes the federal grant activity of the Grady Memorial Hospital Corporation ("GMHC") and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles and Audit Requirements for Federal Awards. As a result, some amounts shown in this schedule may vary from amounts presented in or used in the preparation of the financial statements.
- b. All Federal and State Contractual Assistance Programs are accounted for on the reimbursement basis.

3. Indirect Cost

a. The organization did not use the 10-percent de minimis cost rate allowed under the Uniform Guidance.

b. The Authority uses a provisional indirect cost rate for its grants, contract and other agreements with the Federal Government, approved by the United States Department of Health and Human Services.

In 2019, indirect costs charged to federal programs were as follows:

Sickle Cell	\$ 139,833
Poison Control	35,957
AIDS United HRSA	15,669
Primary Care Training and Enhancement	20,377
Surgical Critical Initiative	 702
Total	\$ 212.538

4. Voucher Distributions

The Authority is the pass-through recipient of federal grant funds from the U. S. Department of Agriculture's Special Supplemental Food for Women, Infants and Children (WIC) Program through Georgia Department of Community Health (the "State"). The Authority identifies eligible program participants and the State issues non-cash food vouchers. According to the State's records, the Authority's WIC program participants received 49,764 vouchers for program year 2019 and redeemed 28,722 vouchers valued at 361,085 for program year 2019.

5. Relationship to Basic Financial Statements and Federal Financial Reports:

Federal and State Contractual Assistance revenues are reported in the GMHC's basic financial statements as follows:

Federal Contractual assistance	\$ 32,557,126
State Contractual assistance	11,130,486
Total per Schedule of Federal and State	
Contractual Assistance	 43,687,612
Medicaid Medical Education Support	12,141,612
Non-federal and state grant revenues	8,878,592
Restricted fund and other revenues, net of WIC Vouchers	
and Workforce Investment Act, and Pell Grants	(530,704)
Miscellaneous	
	 (7,369)
Total grant revenues in GMHC's basic financial statements	\$ 64,169,743

Notes to the Schedule of Federal and State Contractual Assistance December 31, 2019

Total Expenses in GMHC's basic financial statements*	\$	1,325,308,000
Less: Non Grant Related Expenditures		1,247,867,590
Grant Expenditures (Governmental and Non-Governmental)		77,440,410
Less: Grant Expenditures Non-Governmental		33,559,619
Total grant revenues in GMHC's basic financial statements	\$ <u></u>	43,880,791

^{*}Per Note 21 from GMHC financials

6. Pass thru Payments to Sub recipients

In 2019, the Authority made payment to sub recipients:

Agency	Amount		
Sickle Cell	\$	277,561	
Sister Love		16,995	
Deborah W. Bauer		35,893	
Equality Foundation of Georgia		16,330	
Emory University – Primary Care Training		249,552	
Total	\$	596,331	

7. Subsequent Events

During the fourth quarter of 2019, a novel strain of coronavirus (COVID-19) surfaced. The spread of COVID-19 around the world and in the U.S. during the first quarter of 2020 through current has caused significant volatility in the global financial markets, including those in the U.S. There is continued uncertainty as to the breadth and duration of this pandemic and the resultant market disruption. The System is currently evaluating the impact on its operations and financial condition of potential adverse effects specific to the System, including reduced normal patient volumes, capacity constraint and resource inefficiencies due to the surge of COVID-19 patients, unfavorable payor reimbursement patterns and payor mix, and market-driven downward valuation of equity securities, among others.

On March 27, 2020, H.R. 748, the Coronavirus Aid, Relief, and Economic Security Act, "the CARES Act", was signed into legislation. Funding opportunities for healthcare providers under the CARES Act include the Public Health and Social Services Emergency Fund to be distributed to eligible healthcare providers, Centers for Medicare and Medicaid Services Medicare Accelerated/Advanced Payment funding to accelerate three to six months of Medicare payments to eligible healthcare providers, and the Commercial Insurance/FEMA Public Assistance Program: Emergency Protective Measures for reimbursement for eligible emergency costs incurred. In addition to these provisions, the CARES Act also includes various other cash flow enhancement measures such as payroll tax deferrals and employee retention credits, among others. The System has and will continue to consider the provisions of the CARES Act to utilize available governmental funds to offset the immediate effects of the COVID-19 healthcare crisis. The System has evaluated subsequent events through September 30, 2020, the date the consolidated financial statements were available to be issued, and determined that there are no additional items to disclose.

Status of Prior Audit Findings and Questioned Costs For the Year Ended December 31, 2019

Section IV - Schedule of Prior Year Findings and Questioned Costs

No prior year audit findings.